

Verteporfin therapy of subfoveal choroidal neovascular degeneration: two-year results of a randomized clinical occult with no classic choroidal neovascularizationâ€”v therapy report 2

American Journal of Ophthalmology

131, 541-560

DOI: 10.1016/s0002-9394(01)00967-9

Citation Report

#	ARTICLE	IF	CITATIONS
1	Photodynamic therapy with indocyanine green for occult subfoveal choroidal neovascularization caused by age-related macular degeneration. <i>Current Eye Research</i> , 2001, 23, 271-275.	0.7	57
2	Choriocapillaris photodynamic therapy using indocyanine green. <i>American Journal of Ophthalmology</i> , 2001, 132, 557-565.	1.7	66
3	Clinical Trials Digest on the internet at AJO.COM: entering a new information age <sup>21</sup> Reprint requests not available. <sup>22</sup> None of the authors have any proprietary or commercial interests related to the editorial.. <i>American Journal of Ophthalmology</i> , 2001, 132, 566-567.	1.7	2
4	Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy. <i>American Journal of Ophthalmology</i> , 2001, 132, 659-667.	1.7	17
5	Comparison of three techniques of foveal translocation in patients with subfoveal choroidal neovascularization resulting from age-related macular degeneration. <i>American Journal of Ophthalmology</i> , 2001, 132, 888-896.	1.7	87
6	Transpupillary thermotherapy (TTT) of occult choroidal neovascularization: A retrospective, noncomparative case series of fifty-seven eyes. <i>Seminars in Ophthalmology</i> , 2001, 16, 66-69.	0.8	11
7	Efficacy of transpupillary thermotherapy (TTT) in the treatment of occult subfoveal choroidal neovascularization in age-related macular degeneration. <i>Seminars in Ophthalmology</i> , 2001, 16, 81-85.	0.8	22
8	Transpupillary thermotherapy of occult choroidal neovascularization in age-related macular degeneration. <i>Seminars in Ophthalmology</i> , 2001, 16, 86-89.	0.8	12
9	RETINAL ANGIOMATOUS PROLIFERATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2001, 21, 416-434.	1.0	690
10	Fluorescein and indocyanine green angiography after transpupillary thermotherapy of choroidal neovascularization. Early vascular changes. <i>Seminars in Ophthalmology</i> , 2001, 16, 101-105.	0.8	1
11	Transpupillary thermotherapy (TTT) for age-related macular degeneration. <i>Seminars in Ophthalmology</i> , 2001, 16, 70-80.	0.8	5
13	Photodynamic therapy with verteporfin: A new treatment in ophthalmology. <i>Seminars in Ophthalmology</i> , 2001, 16, 201-206.	0.8	58
14	Verteporfin for Age-Related Macular Degeneration. <i>Annals of Pharmacotherapy</i> , 2001, 35, 1593-1598.	0.9	36
15	A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss. <i>JAMA Ophthalmology</i> , 2001, 119, 1417.	2.6	2,881
17	Photodynamic therapy of age-related macular degeneration: History and principles. <i>Seminars in Ophthalmology</i> , 2001, 16, 181-200.	0.8	57
18	Development of verteporfin therapy: A collaboration between pharmaceutical companies, device manufacturers and clinical investigators. <i>Seminars in Ophthalmology</i> , 2001, 16, 213-217.	0.8	6
19	Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: From clinical trials to clinical practice. <i>Seminars in Ophthalmology</i> , 2001, 16, 207-212.	0.8	11
20	Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD. <i>Seminars in Ophthalmology</i> , 2001, 16, 223-232.	0.8	0

#	ARTICLE	IF	CITATIONS
21	Clinical Pharmacokinetics of Verteporfin. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 547-557.	1.0	75
22	Photodynamic therapy systems and applications. <i>Expert Opinion on Emerging Drugs</i> , 2002, 7, 321-334.	1.0	42
23	An update on photodynamic therapy in age-related macular degeneration. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 931-938.	0.9	30
24	Visual Outcomes Following Macular Translocation With 360° Peripheral Retinectomy. <i>JAMA Ophthalmology</i> , 2002, 120, 1317.	2.6	77
25	Limited macular translocation with scleral retraction suture. <i>British Journal of Ophthalmology</i> , 2002, 86, 434-439.	2.1	6
26	Recent Advances in the Management of Age-Related Macular Degeneration. <i>Optometry and Vision Science</i> , 2002, 79, 218-224.	0.6	20
27	Photodynamic therapy for age-related macular degeneration. <i>Age and Ageing</i> , 2002, 31, 5-6.	0.7	0
28	Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. <i>British Journal of Ophthalmology</i> , 2002, 86, 663-669.	2.1	26
29	Submacular Surgery Trials update. <i>Ophthalmology Clinics of North America</i> , 2002, 15, 479-488.	1.8	5
30	GUIDELINES FOR USING VERTEPORFIN (VISUDYNE®) IN PHOTODYNAMIC THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES. <i>Retina</i> , 2002, 22, 6-18.	1.0	195
31	PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2002, 22, 391-405.	1.0	57
32	TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY WITH PHOTODYNAMIC THERAPY. <i>Retina</i> , 2002, 22, 529-535.	1.0	169
33	TREATMENT OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH MULTIFOCAL CHOROIDITIS AND PANUVEITIS WITH PHOTODYNAMIC THERAPY. <i>Retina</i> , 2002, 22, 545-549.	1.0	80
34	DURATION OF SKIN PHOTOSENSITIVITY AND INCIDENCE OF PHOTOSENSITIVITY REACTIONS AFTER ADMINISTRATION OF VERTEPORFIN. <i>Retina</i> , 2002, 22, 691-697.	1.0	35
35	LOCALIZATION OF ROSE BENGAL, ALUMINUM PHTHALOCYANINE TETRASULFONATE, AND CHLORIN e6 IN THE RABBIT EYE. <i>Retina</i> , 2002, 22, 65-74.	1.0	13
36	THE NATURE OF FOCAL AREAS OF HYPERFLUORESCENCE OR "HOT SPOTS" IMAGED WITH INDOCYANINE GREEN ANGIOGRAPHY. <i>Retina</i> , 2002, 22, 557-568.	1.0	68
37	Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Patients With Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2002, 120, 1443.	2.6	181
38	Photodynamic therapy for choroidal neovascular disease: photosensitizers and clinical trials. <i>Ophthalmology Clinics of North America</i> , 2002, 15, 473-478.	1.8	25

#	ARTICLE	IF	CITATIONS
39	Photodynamic therapy for circumscribed choroidal hemangioma. Canadian Journal of Ophthalmology, 2002, 37, 314-317.	0.4	13
40	Photodynamic therapy increases the eligibility for feeder vessel treatment of choroidal neovascularization caused by age-related macular degeneration. American Journal of Ophthalmology, 2002, 133, 572-575.	1.7	15
41	Radiotherapy for subfoveal choroidal neovascularization in age-related macular degeneration: a randomized clinical trial. American Journal of Ophthalmology, 2002, 133, 521-529.	1.7	54
42	Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration. American Journal of Ophthalmology, 2002, 133, 857.	1.7	14
43	Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin 1 1InternetAdvance publication at ajo.com June 7, 2002.. American Journal of Ophthalmology, 2002, 134, 62-68.	1.7	64
44	Treatment of juxtafoveal and extrafoveal choroidal neovascularization in the era of photodynamic therapy with verteporfin. American Journal of Ophthalmology, 2002, 134, 99-101.	1.7	21
45	Adverse reaction characterized by chest pain, shortness of breath, and syncope associated with verteporfin (visudyne). American Journal of Ophthalmology, 2002, 134, 281-282.	1.7	17
46	Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. American Journal of Ophthalmology, 2002, 134, 277-280.	1.7	98
47	Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks. American Journal of Ophthalmology, 2002, 134, 360-366.	1.7	69
48	Macular translocation with 360 degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. American Journal of Ophthalmology, 2002, 134, 560-565.	1.7	106
49	Detachment of subfoveal choroidal neovascularization in age-related macular degeneration. American Journal of Ophthalmology, 2002, 134, 822-827.	1.7	6
50	An Update on Photodynamic Therapy Applications. Photomedicine and Laser Surgery, 2002, 20, 3-7.	1.1	478
51	Age-Related Macular Degeneration. Drugs and Aging, 2002, 19, 101-133.	1.3	98
52	Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome. Ophthalmology, 2002, 109, 1499-1505.	2.5	80
53	Dietary antioxidant intake and incidence of early age-related maculopathy11The authors have no financial interest in any industry brands named in the manuscript.. Ophthalmology, 2002, 109, 2272-2278.	2.5	105
55	Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmologica, 2002, 80, 136-143.	0.4	61
56	New Laser Treatment Options in Age-related Macular Degeneration: Transpupillary Thermo-therapy. Medical Laser Application: International Journal for Laser Treatment and Research, 2002, 17, 297-304.	0.4	1
57	Age-Related Macular Degeneration and Retinal Pigment Epithelium Wound Healing. Molecular Neurobiology, 2003, 28, 177-194.	1.9	21

#	ARTICLE	IF	CITATIONS
58	The changes of multifocal electroretinography in the early stage of photodynamic therapy for choroidal neovascularization. <i>Documenta Ophthalmologica</i> , 2003, 107, 165-170.	1.0	18
59	Photodynamic Therapy for Subfoveal Choroidal Neovascularisation in Various Diseases among which Age-related Macular Degeneration: An Update. <i>Medical Laser Application: International Journal for Laser Treatment and Research</i> , 2003, 18, 65-78.	0.4	5
60	Photodynamic therapy for choroidal neovascularization. , 2003, 241, 258-262.		8
64	Review Article. New treatments in age-related macular degeneration. <i>Clinical and Experimental Ophthalmology</i> , 2003, 31, 376-391.	1.3	49
65	Photodynamic therapy in practice: a review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital. <i>Clinical and Experimental Ophthalmology</i> , 2003, 31, 476-481.	1.3	15
66	Age-related macular disease: an ongoing challenge. <i>Clinical and Experimental Ophthalmology</i> , 2003, 31, 461-463.	1.3	7
67	Photodynamic therapy with delayed light application for the treatment of bilateral subfoveal choroidal neovascularization in age-related macular degeneration. <i>Japanese Journal of Ophthalmology</i> , 2003, 47, 595-598.	0.9	1
68	Lipid-derivatized poly(ethylene glycol) micellar formulations of benzoporphyrin derivatives. <i>Journal of Controlled Release</i> , 2003, 86, 323-338.	4.8	29
69	Transpupillary thermotherapy of predominantly occult choroidal neovascularization in age-related macular degeneration with 12 months follow-up. <i>Acta Ophthalmologica</i> , 2003, 81, 110-117.	0.4	38
70	Prophylactic laser treatment in early age-related maculopathy: an 8-year follow-up in a randomized pilot study shows a reduced incidence of exudative complications. <i>Acta Ophthalmologica</i> , 2003, 81, 449-454.	0.4	19
71	Verteporfin photodynamic therapy in the UK: implications of the NICE appraisal. <i>Eye</i> , 2003, 17, 119-122.	1.1	2
72	Towards an understanding of age-related macular disease. <i>Eye</i> , 2003, 17, 457-466.	1.1	92
73	Ocular therapeutics. <i>Australasian journal of optometry, The</i> , 2003, 86, 63-64.	0.6	1
74	Verteporfin. <i>Drugs</i> , 2003, 63, 2521-2554.	4.9	32
75	Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. <i>American Journal of Ophthalmology</i> , 2003, 135, 343-350.	1.7	65
76	Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. <i>American Journal of Ophthalmology</i> , 2003, 136, 407-418.	1.7	278
77	Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. <i>American Journal of Ophthalmology</i> , 2003, 136, 1049-1061.	1.7	92
78	The histopathologic effects of transpupillary thermotherapy in human eyes. <i>Ophthalmology</i> , 2003, 110, 415-420.	2.5	37

#	ARTICLE	IF	CITATIONS
79	Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration. <i>Ophthalmology</i> , 2003, 110, 65-69.	2.5	100
80	Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). <i>Ophthalmology</i> , 2003, 110, 400-405.	2.5	70
81	Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia. <i>Ophthalmology</i> , 2003, 110, 667-673.	2.5	370
82	Replacing the Amsler grid. <i>Ophthalmology</i> , 2003, 110, 966-970.	2.5	108
83	Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. <i>Ophthalmology</i> , 2003, 110, 1306-1314.	2.5	57
84	Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. <i>Ophthalmology</i> , 2003, 110, 1517-1525.	2.5	302
85	Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization. <i>Ophthalmology</i> , 2003, 110, 2395-2402.	2.5	60
86	Morphologic and angiographic assessment of the macula after macular translocation surgery with 360° retinotomy. <i>Ophthalmology</i> , 2003, 110, 2403-2408.	2.5	20
87	CNV subtype in first eyes predicts severity of ARM in fellow eyes. <i>British Journal of Ophthalmology</i> , 2003, 87, 307-311.	2.1	20
88	Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia. <i>British Journal of Ophthalmology</i> , 2003, 87, 177-183.	2.1	22
89	Retinal Pigment Epithelium Wound Healing in Human Bruchâ€™s Membrane Explants. , 2003, 44, 2199.		55
90	Visual hallucinations and Charles Bonnet syndrome after photodynamic therapy for age related macular degeneration. <i>British Journal of Ophthalmology</i> , 2003, 87, 977-979.	2.1	30
91	Optic disc morphology in south India: the Vellore Eye Study. <i>British Journal of Ophthalmology</i> , 2003, 87, 189-196.	2.1	49
92	Sequence of Early Vascular Events after Photodynamic Therapy. , 2003, 44, 2147.		177
94	Photodynamic Therapy of Subfoveal Choroidal Neovascularization With Verteporfin. <i>JAMA Ophthalmology</i> , 2003, 121, 1253.	2.6	215
95	A Randomized Clinical Trial of a Single Dose of Intravitreal Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2003, 121, 667.	2.6	357
97	CASE SERIES OUTCOMES AT 1 WEEK FOLLOWING VERTEPORFIN PHOTODYNAMIC THERAPY. <i>Retina</i> , 2003, 23, 166-170.	1.0	2
98	Update on Photodynamic Therapy. <i>Current Opinion in Ophthalmology</i> , 2003, 14, 163-168.	1.3	9

#	ARTICLE	IF	CITATIONS
99	PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH PATTERN DYSTROPHY. <i>Retina</i> , 2003, 23, 171-176.	1.0	36
100	IMMEDIATE INDOCYANINE GREEN ANGIOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY EVALUATION AFTER PHOTODYNAMIC THERAPY FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2003, 23, 159-165.	1.0	93
101	TRANSPUPILLARY THERMOTHERAPY THRESHOLD PARAMETERS. <i>Retina</i> , 2003, 23, 378-386.	1.0	14
102	ANGIOGRAPHIC CHARACTERISTICS IN PATIENTS UNDERGOING MACULAR TRANSLOCATION FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2003, 23, 152-158.	1.0	4
103	INDOCYANINE GREEN ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2003, 23, 288-298.	1.0	391
104	Common Eye Diseases of Elderly People: Identifying and Treating Causes of Vision Loss. <i>Gerontology</i> , 2003, 49, 1-11.	1.4	57
105	Gene therapy for ocular angiogenesis. <i>Clinical Science</i> , 2003, 104, 561-575.	1.8	45
106	Large Spot Size Transpupillary Thermotherapy for the Treatment of Occult Choroidal Neovascularization Associated With Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2003, 121, 817.	2.6	31
107	Lack of an Association of Apolipoprotein E Gene Polymorphisms With Familial Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2003, 121, 679.	2.6	67
108	Sequential Combined Therapy for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration: Photodynamic Therapy and Thermal Laser Photocoagulation. <i>European Journal of Ophthalmology</i> , 2003, 13, 681-686.	0.7	3
109	Subfoveal Choroidal Neovascularization in a Patient with Pre-Existing Pseudomacular Hole. <i>European Journal of Ophthalmology</i> , 2003, 13, 718-721.	0.7	1
110	A Preliminary Assessment of Macular Function by MF-ERG in Myopic Eyes with CNV with Complete Response to Photodynamic Therapy. <i>European Journal of Ophthalmology</i> , 2003, 13, 461-467.	0.7	17
111	Lacquer Crack Formation after Photodynamic Therapy. <i>European Journal of Ophthalmology</i> , 2003, 13, 729-733.	0.7	15
113	Treatment of Age-Related Macular Degeneration. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 166-169.	1.1	4
114	Bilateral Cnv Associated with Optic Nerve Drusen Treated with Photodynamic Therapy with Verteporfin. <i>European Journal of Ophthalmology</i> , 2004, 14, 434-437.	0.7	25
115	Preserving vision with verteporfin photodynamic therapy. <i>British Journal of Hospital Medicine</i> , 2004, 65, 39-43.	0.3	2
116	Natural History of Minimally Classic Subfoveal Choroidal Neovascular Lesions in the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation. <i>JAMA Ophthalmology</i> , 2004, 122, 325.	2.6	24
118	Is Coxsackievirus the Cause of Unilateral Acute Idiopathic Maculopathy?. <i>JAMA Ophthalmology</i> , 2004, 122, 121.	2.6	69

#	ARTICLE	IF	CITATIONS
119	Colour vision testing as an aid to diagnosis and management of age related maculopathy. British Journal of Ophthalmology, 2004, 88, 1180-1185.	2.1	45
120	BDNF Reduces the Retinal Toxicity of Verteporfin Photodynamic Therapy. , 2004, 45, 4190.		31
121	Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. British Journal of Ophthalmology, 2004, 88, 207-211.	2.1	25
122	Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review. British Journal of Ophthalmology, 2004, 88, 212-217.	2.1	24
123	Indocyanine green mediated photothrombosis for the management of predominantly classic choroidal neovascularisation caused by age related macular degeneration. British Journal of Ophthalmology, 2004, 88, 1055-1059.	2.1	10
124	Treatment and Prevention of Age-Related Macular Degeneration. Journal of Pharmacy Practice and Research, 2004, 34, 53-57.	0.5	1
125	Subthreshold transpupillary thermotherapy for subfoveal occult choroidal neovascularization secondary to age-related macular degeneration. Seminars in Ophthalmology, 2004, 19, 25-28.	0.8	2
126	Radiotherapy for recurrent choroidal neovascularisation complicating age related macular degeneration. British Journal of Ophthalmology, 2004, 88, 114-119.	2.1	14
127	Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. British Journal of Ophthalmology, 2004, 88, 344-347.	2.1	141
128	Outcome of Transplantation of Autologous Retinal Pigment Epithelium in Age-Related Macular Degeneration: A Prospective Trial. , 2004, 45, 4151.		211
129	Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration. Acta Ophthalmologica, 2004, 82, 645-650.	0.4	17
130	Photodynamic therapy with verteporfin in patients with age-related macular degeneration and juxtafoveal choroidal neovascularization. Acta Ophthalmologica, 2004, 82, 651-655.	0.4	5
131	Photodynamic therapy for AMD: smaller is better!. Acta Ophthalmologica, 2004, 82, 641-642.	0.4	1
132	The incidence and outcome of photodynamic therapy for macular degeneration in the Northern Region of the UK. Eye, 2004, 18, 588-594.	1.1	8
133	Outcomes in verteporfin photodynamic therapy for choroidal neovascularisationâ€”beyond the TAP studyâ€™. Eye, 2004, 18, 809-813.	1.1	24
134	Correspondence. Influence of lesion size on treatment benefit with photodynamic therapy. Clinical and Experimental Ophthalmology, 2004, 32, 452-453.	1.3	0
135	Long-term results after surgical extraction of subfoveal choroidal neovascular membranes with and without haemorrhage in age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2004, 242, 350-354.	1.0	6
136	Stabilization of visual acuity with photodynamic therapy in eyes with chorioretinal anastomoses. Graefe's Archive for Clinical and Experimental Ophthalmology, 2004, 242, 368-376.	1.0	22

#	ARTICLE	IF	CITATIONS
137	Photodynamic Therapy in Patients with Idiopathic Choroidal Neovascularization. Japanese Journal of Ophthalmology, 2004, 48, 422-424.	0.9	1
143	On the selectivity of photodynamic therapy of choroidal neovascularization associated with age-related macular degeneration. Journal Francais D'Ophtalmologie, 2004, 27, 75-78.	0.2	14
144	Assessment of macular function by multifocal electroretinogram in age-related macular degeneration before and after photodynamic therapy. Journal Francais D'Ophtalmologie, 2004, 27, 1001-1006.	0.2	18
146	Retinal angiomatous proliferation: clinical characteristics and treatment options. Optometry - Journal of the American Optometric Association, 2004, 75, 577-588.	0.6	27
147	Current and Future Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration. Drugs and Aging, 2004, 21, 967-992.	1.3	29
148	Spotlight on Verteporfin in Subfoveal Choroidal Neovascularisation1. Drugs and Aging, 2004, 21, 203-209.	1.3	6
149	Transpupillary thermotherapy in the management of circumscribed choroidal hemangioma. Survey of Ophthalmology, 2004, 49, 316-327.	1.7	92
150	Fluorescein angiographic lesion type frequency in neovascular Age-Related macular degeneration11 Drs Olsen and Steuer serve as retinal consultants to the Northwest Eye Clinic, Plymouth, Minnesota.. Ophthalmology, 2004, 111, 250-255.	2.5	77
151	Effects of verteporfin therapy on central visual field function. Ophthalmology, 2004, 111, 931-939.	2.5	53
152	Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. Ophthalmology, 2004, 111, 1576-1584.	2.5	278
153	Photodynamic therapy with verteporfin in ocular histoplasmosis: Uncontrolled, open-label 2-year study. Ophthalmology, 2004, 111, 1725-1733.	2.5	75
154	Change in visual function after macular translocation with 360° retinectomy for neovascular age-related macular degeneration. Ophthalmology, 2004, 111, 1715-1724.	2.5	90
155	Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findingsSST report no. 11. Ophthalmology, 2004, 111, 1967-1980.	2.5	172
156	Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic findingsSST report no. 13. Ophthalmology, 2004, 111, 1993-2006.e1.	2.5	258
157	Large submacular hemorrhages after verteporfin therapy. American Journal of Ophthalmology, 2004, 137, 558-560.	1.7	21
158	Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns. American Journal of Ophthalmology, 2004, 137, 258-264.	1.7	47
159	Intraocular availability of triamcinolone acetonide after intravitreal injection. American Journal of Ophthalmology, 2004, 137, 560-562.	1.7	105
160	Photodynamic therapy for age-related macular degeneration: a candid appraisal. American Journal of Ophthalmology, 2004, 137, 483-485.	1.7	15

#	ARTICLE	IF	CITATIONS
161	Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials—TAP and VIP report no. 3. American Journal of Ophthalmology, 2004, 137, 683-696.	1.7	144
162	Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. American Journal of Ophthalmology, 2004, 137, 812-819.	1.7	45
163	Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. American Journal of Ophthalmology, 2004, 137, 826-833.	1.7	113
164	Predictors of structural findings in old disciform lesions. American Journal of Ophthalmology, 2004, 138, 245-253.	1.7	12
165	Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. American Journal of Ophthalmology, 2004, 138, 434-438.	1.7	54
166	Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. American Journal of Ophthalmology, 2004, 138, 803-808.	1.7	80
167	Neuroprotection in ophthalmology: a review. Brain Research Bulletin, 2004, 62, 447-453.	1.4	38
168	Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials—TAP and VIP report no. 3*1. American Journal of Ophthalmology, 2004, 137, .	1.7	2
169	VERTEPORFIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (VAM): An Open-label Multicenter Photodynamic Therapy Study of 4,435 Patients. Retina, 2004, 24, 512-520.	1.0	41
170	FLUORESCEIN ANGIOGRAPHIC LESION TYPE FREQUENCY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Evidence-Based Eye Care, 2004, 5, 167-169.	0.2	1
171	Treatment of age-related macular degeneration. Journal of the Royal Society of Medicine, 2004, 97, 166-169.	1.1	4
172	VERTEPORFIN THERAPY OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2004, 24, 1-12.	1.0	93
173	INCIDENCE OF LASER PHOTOCOAGULATION AND PHOTODYNAMIC THERAPY WITH VERTEPORFIN AT A TERTIARY RETINAL CENTER. Retina, 2004, 24, 13-18.	1.0	12
174	Macular Translocation With 360-Degree Retinotomy for Treatment of Exudative Age-Related Macular Degeneration. International Ophthalmology Clinics, 2004, 44, 73-81.	0.3	6
175	PHOTODYNAMIC THERAPY AND VITELLIFORM LESIONS. Retina, 2004, 24, 399-406.	1.0	21
176	RETROSPECTIVE CASE SERIES OF JUXTAFOVEAL CHOROIDAL NEOVASCULARIZATION TREATED WITH PHOTODYNAMIC THERAPY WITH VERTEPORFIN. Retina, 2004, 24, 501-506.	1.0	21
177	NATURAL HISTORY OF MINIMALLY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULAR LESIONS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY (TAP) INVESTIGATION. Evidence-Based Eye Care, 2004, 5, 152-153.	0.2	0
178	Innovative Treatments for Exudative Age-Related Macular Degeneration. International Ophthalmology Clinics, 2004, 44, 41-50.	0.3	6

#	ARTICLE	IF	CITATIONS
179	OUTCOME OF CHOROIDAL NEOVASCULARIZATION IN ANGIOID STREAKS AFTER PHOTODYNAMIC THERAPY. <i>Retina</i> , 2004, 24, 763-771.	1.0	87
180	CHANGES IN LESION SIZE AFTER SUBMACULAR SURGERY FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN THE SUBMACULAR SURGERY TRIALS PILOT STUDY. <i>Retina</i> , 2004, 24, 888-899.	1.0	8
181	Photodynamic Therapy of Subfoveal Choroidal Neovascularization with Verteporfin. <i>Evidence-Based Eye Care</i> , 2004, 5, 10-12.	0.2	1
182	Photodynamic Therapy With Verteporfin in Subfoveal Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy. <i>JAMA Ophthalmology</i> , 2004, 122, 37.	2.6	45
183	Morphometric Analysis of Angiograms of Exudative Lesions in Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2004, 122, 710.	2.6	14
185	Photodynamic Therapy for Occult Choroidal Neovascularization With Pigment Epithelium Detachment in Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2004, 122, 453.	2.6	69
186	NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2005, 25, 1065-1084.	1.0	94
187	CORRESPONDENCE. <i>Retina</i> , 2005, 25, 102-103.	1.0	2
188	TRANSLUMENAL ND:YAG LASER EMBOLYSIS FOR CENTRAL RETINAL ARTERY OCCLUSION. <i>Retina</i> , 2005, 25, 797-799.	1.0	21
189	Medical Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. <i>International Ophthalmology Clinics</i> , 2005, 45, 115-132.	0.3	39
190	Age-related macular degeneration. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005, 66, 677-681.	0.2	2
191	CORRESPONDENCE. <i>Retina</i> , 2005, 25, 101-102.	1.0	4
192	RESULTS OF A MULTICENTER CLINICAL TRIAL TO EVALUATE THE PREFERENTIAL HYPERACUITY PERIMETER FOR DETECTION OF AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2005, 25, 296-303.	1.0	82
193	EFFECT OF VITRECTOR CUTTING RATE ON VITREOUS BIOPSY YIELD. <i>Retina</i> , 2005, 25, 795-797.	1.0	13
194	RETINAL VASCULOPATHY IN FANCONI ANEMIA: A CASE REPORT. <i>Retina</i> , 2005, 25, 799-800.	1.0	15
195	A CASE OF INTRAVITREAL SILICONE OIL MIGRATION TO THE CENTRAL NERVOUS SYSTEM. <i>Retina</i> , 2005, 25, 791-793.	1.0	33
196	GUIDELINES FOR USING VERTEPORFIN (VISUDYNE) IN PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES: UPDATE. <i>Retina</i> , 2005, 25, 119-134.	1.0	154
197	PREVALENCE OF PATIENTS PRESENTING WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN AN URBAN POPULATION. <i>Retina</i> , 2005, 25, 324-331.	1.0	18

#	ARTICLE	IF	CITATIONS
198	INDOCYANINE GREEN-MEDIATED PHOTOTHROMBOSIS WITH AND WITHOUT INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Retina, 2005, 25, 719-726.	1.0	10
199	PRESUMED INTRAOCULAR METASTASIS OF A GLANS PENIS MELANOMA. Retina, 2005, 25, 788-789.	1.0	0
200	MULTIFUNCTION DELAMINATION SCISSORS FOR VITREOUS SURGERY. Retina, 2005, 25, 789-790.	1.0	1
201	HEPARIN-ASSISTED REMOVAL OF CLOTTING PRERETINAL HEMORRHAGE DURING VITRECTOMY FOR PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2005, 25, 793-795.	1.0	7
202	PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR PERIPAPILLARY CHOROIDAL NEOVASCULARIZATION. Retina, 2005, 25, 33-37.	1.0	37
203	SUBRETINAL SURGERY FOR PERIPAPILLARY SUBRETINAL NEOVASCULAR MEMBRANES. Retina, 2005, 25, 564-569.	1.0	16
204	COMPLICATIONS AND LACK OF BENEFIT AFTER TRANSPUPILLARY THERMOTHERAPY FOR OCCULT CHOROIDAL NEOVASCULARIZATION: 1-YEAR RESULTS. Retina, 2005, 25, 784-788.	1.0	11
205	GUIDELINES FOR INTERPRETING RETINAL PHOTOGRAPHS AND CODING FINDINGS IN THE SUBMACULAR SURGERY TRIALS (SST). Retina, 2005, 25, 253-268.	1.0	23
206	A CASE OF BILATERAL RETINAL VASCULITIS ASSOCIATED WITH SWEET SYNDROME. Retina, 2005, 25, 800-802.	1.0	17
207	Photodynamic therapy for neovascular age-related macular degeneration. , 2005, , CD002030.		34
208	Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: Clinical experience and practicalities. Journal of Photochemistry and Photobiology B: Biology, 2005, 79, 211-222.	1.7	179
209	Objective functional assessment of age-related maculopathy: a special application for the multifocal electroretinogram. Australasian journal of optometry, The, 2005, 88, 304-312.	0.6	24
210	Treatment of age-related macular degeneration. Australasian journal of optometry, The, 2005, 88, 322-334.	0.6	21
211	Photodynamic therapy for maculopathy due to radiation retinopathy. Eye, 2005, 19, 795-799.	1.1	44
212	Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration. Eye, 2005, 19, 1142-1150.	1.1	59
213	Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD. Eye, 2005, 19, 1315-1324.	1.1	56
214	Transpupillary thermotherapy for occult subfoveal choroidal neovascularization: a 1-year, prospective randomized pilot study. Acta Ophthalmologica, 2005, 83, 148-153.	0.4	7
215	Natural course of occult choroidal neovascularization in age-related macular degeneration: development of classic lesions in fluorescein angiography. Acta Ophthalmologica, 2005, 83, 141-147.	0.4	15

#	ARTICLE	IF	CITATIONS
216	A new animal model of choroidal neovascularization. <i>Acta Ophthalmologica</i> , 2005, 83, 697-704.	0.4	40
219	Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2005, 243, 973-979.	1.0	138
220	Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2005, 243, 829-833.	1.0	26
223	Electrooculography After Photodynamic Therapy. <i>Documenta Ophthalmologica</i> , 2005, 111, 83-86.	1.0	13
224	The Changes of Pattern Electroretinography at the Early Stage of Photodynamic Therapy. <i>Documenta Ophthalmologica</i> , 2005, 111, 107-112.	1.0	15
225	Dynamics of Retinal Function after Multiple Photodynamic Therapies in Age-Related Macular Degeneration: A Report of Cases. <i>Documenta Ophthalmologica</i> , 2005, 111, 135-148.	1.0	12
226	Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]. <i>BMC Ophthalmology</i> , 2005, 5, 27.	0.6	5
228	Photodynamic Therapy With Verteporfin. <i>JAMA Ophthalmology</i> , 2005, 123, 58.	2.6	12
229	Photodynamic Therapy: Current Guidelines for the Management of Neovascular Age-Related Macular Degeneration. <i>Essentials in Ophthalmology</i> , 2005, , 129-141.	0.0	0
230	Result of Photodynamic Therapy for Idiopathic Subfoveal Choroidal Neovascularization. <i>Korean Journal of Ophthalmology: KJO</i> , 2005, 19, 264.	0.5	9
231	Mechanism of Photodynamic Occlusion Using Liposomal Zn(II)-Phtalocyanine. <i>Current Eye Research</i> , 2005, 30, 601-612.	0.7	4
232	Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration. <i>British Journal of Ophthalmology</i> , 2005, 89, 312-315.	2.1	22
233	Treatment of Retinal Angiomatous Proliferation in Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2005, 123, 1644.	2.6	126
234	Safety and Efficacy of Intravitreal Injection of Ranibizumab in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization in the Monkey. <i>JAMA Ophthalmology</i> , 2005, 123, 509.	2.6	96
235	Verteporfin therapy in combination with triamcinolone: published studies investigating a potential synergistic effect. <i>Current Medical Research and Opinion</i> , 2005, 21, 705-713.	0.9	30
236	Complications After Photodynamic Therapy. <i>JAMA Ophthalmology</i> , 2005, 123, 1347.	2.6	34
237	Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 119-135.	1.0	5
238	Photodynamic Therapy for Subfoveal Classic Choroidal Neovascularization Related to Punctate Inner Choroidopathy (PIC) or Presumed Ocular Histoplasmosis-Like Syndrome (POHS-Like). <i>Ocular Immunology and Inflammation</i> , 2005, 13, 361-366.	1.0	35

#	ARTICLE	IF	CITATIONS
239	Photodynamic Therapy for Inflammatory CNV: Do We Know Enough?. <i>Ocular Immunology and Inflammation</i> , 2005, 13, 331-333.	1.0	5
240	Verteporfin Therapy of Subfoveal Minimally Classic Choroidal Neovascularization in Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2005, 123, 448.	2.6	191
241	Retinal Anastomosis to Choroidal Neovascularization. <i>JAMA Ophthalmology</i> , 2005, 123, 1741.	2.6	32
242	Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes. <i>British Journal of Ophthalmology</i> , 2005, 89, 967-970.	2.1	53
243	Choroidal Infarction Following Photodynamic Therapy With Verteporfin. <i>JAMA Ophthalmology</i> , 2005, 123, 1149.	2.6	48
244	Photodynamic Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration. <i>Journal of the Chinese Medical Association</i> , 2005, 68, 419-424.	0.6	5
245	Socioeconomic status and clinical features of patients undergoing photodynamic therapy or transpupillary thermotherapy for subfoveal choroidal neovascularization due to age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , 2005, 40, 384-388.	0.4	8
246	Comparison of photodynamic therapy and transpupillary thermotherapy for subfoveal choroidal neovascularization due to age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , 2005, 40, 378-383.	0.4	7
247	Laser prophylaxis for age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , 2005, 40, 320-331.	0.4	10
248	Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. <i>Ophthalmology</i> , 2005, 112, 301-304.	2.5	227
249	Maximum Tolerated Dose of a Humanized Anti-VEGF Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2005, 112, 1048-1053.e4.	2.5	219
250	Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration Twelve-Week Results of an Uncontrolled Open-Label Clinical Study. <i>Ophthalmology</i> , 2005, 112, 1035-1047.e9.	2.5	626
251	Preferential Hyperacuity Perimeter (PreView PHP) for Detecting Choroidal Neovascularization Study. <i>Ophthalmology</i> , 2005, 112, 1758-1765.	2.5	83
252	Comparison of Early Retreatment with the Standard Regimen in Verteporfin Therapy of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2005, 112, 2070-2075.	2.5	14
253	Time Course and Morphology of Vascular Effects Associated with Photodynamic Therapy. <i>Ophthalmology</i> , 2005, 112, 2061-2069.	2.5	76
254	Verteporfin photodynamic therapy for the treatment of persistent subfoveal choroidal neovascularization after external beam radiotherapy: One-year results. <i>American Journal of Ophthalmology</i> , 2005, 139, 561-562.	1.7	2
255	Age-related macular degeneration 1969-2004: A 35-year personal perspective. <i>American Journal of Ophthalmology</i> , 2005, 139, 405-420.	1.7	36
256	Using Optical Coherence Tomography to Monitor Photodynamic Therapy in Age Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2005, 140, 23.e1-23.e7.	1.7	72

#	ARTICLE	IF	CITATIONS
257	Clinical Strategies for Diagnosis and Treatment of AMD: Implications from Research. , 2005, , 167-200.		5
258	Age-related Macular Disease: How to assess the retina using scanning laser techniques?. Aging Clinical and Experimental Research, 2005, 17, 435-444.	1.4	4
259	Verteporfin. Drugs and Aging, 2006, 23, 421-445.	1.3	21
260	Neuroprotection in Ophthalmology: A Review. , 2006, , 237-249.		1
261	Flavonoids Protect Human Retinal Pigment Epithelial Cells from Oxidative-Stressâ€œInduced Death. , 2006, 47, 3164.		270
262	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opinion on Pharmacotherapy, 2006, 7, 2355-2368.	0.9	8
263	Anecortave acetate. Expert Opinion on Investigational Drugs, 2006, 15, 163-169.	1.9	5
264	Toxicity of Subretinal Ribozyme to the Proliferating Cell Nuclear Antigen and 5-Fluorouracil in Rat Eyes. Current Eye Research, 2006, 31, 435-440.	0.7	1
265	Photodynamic Therapy of Experimental Choroidal Neovascularization in the Mouse. Current Eye Research, 2006, 31, 765-774.	0.7	16
266	Promising new treatments for neovascular age-related macular degeneration. Expert Opinion on Investigational Drugs, 2006, 15, 779-793.	1.9	68
267	Ranibizumab for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine, 2006, 355, 1419-1431.	13.9	5,190
269	A Preliminary Benefit-Risk Assessment of Verteporfin in Age-Related Macular Degeneration. Drug Safety, 2006, 29, 189-199.	1.4	12
270	Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine, 2006, 355, 1432-1444.	13.9	3,221
271	Ageâ€œrelated macular degenerationâ€œemerging pathogenetic and therapeutic concepts. Annals of Medicine, 2006, 38, 450-471.	1.5	546
272	Rationale for Combination Therapies for Choroidal Neovascularization. American Journal of Ophthalmology, 2006, 141, 149-156.	1.7	112
273	Verteporfin and Intravitreal Triamcinolone Acetonide Combination Therapy for Occult Choroidal Neovascularization in Age-Related Macular Degeneration. American Journal of Ophthalmology, 2006, 141, 638-638.e10.	1.7	95
274	Expression of VEGF and PEDF in Choroidal Neovascular Membranes Following Verteporfin Photodynamic Therapy. American Journal of Ophthalmology, 2006, 142, 95-104.e1.	1.7	92
275	Autologous Translocation of the Choroid and Retinal Pigment Epithelium in Age-related Macular Degeneration. American Journal of Ophthalmology, 2006, 142, 17-30.e8.	1.7	137

#	ARTICLE	IF	CITATIONS
276	Photodynamic Therapy With Verteporfin and Intravitreal Triamcinolone Acetonide in the Treatment of Neovascular Age-related Macular Degeneration. American Journal of Ophthalmology, 2006, 142, 10-16.e1.	1.7	37
277	Choroidal Ischemia After Photodynamic Therapy With Verteporfin for Choroidal Neovascularization. American Journal of Ophthalmology, 2006, 142, 680-683.	1.7	46
278	Progression of Choroidal Neovascularization Following Injection of Pegaptanib Sodium (Macugen) in Two Eyes With Neovascular Age-related Macular Degeneration. American Journal of Ophthalmology, 2006, 142, 683-685.e1.	1.7	6
279	Triple Therapy of Intravitreal Triamcinolone, Photodynamic Therapy, and Pegaptanib Sodium for Choroidal Neovascularization. American Journal of Ophthalmology, 2006, 142, 1072-1074.	1.7	35
280	Verteporfin Therapy Combined with Intravitreal Triamcinolone in All Types of Choroidal Neovascularization due to Age-Related Macular Degeneration. Ophthalmology, 2006, 113, 14-22.	2.5	166
281	Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2006, 113, 992-1001.e6.	2.5	239
282	Proton Beam Irradiation for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2006, 113, 2012-2019.	2.5	46
283	Laser Treatment in Patients with Bilateral Large Drusen. Ophthalmology, 2006, 113, 1974-1986.	2.5	73
284	Influence of Treatment Parameters on Selectivity of Verteporfin Therapy. , 2006, 47, 371.		104
285	Dose-Ranging Study of Lutein Supplementation in Persons Aged 60 Years or Older. , 2006, 47, 5227.		61
286	Effect of Intravitreal Injection of Ranibizumab in Combination with Verteporfin PDT on Normal Primate Retina and Choroid. , 2006, 47, 357.		53
287	Lesion Morphology in Age-Related Macular Degeneration and Its Therapeutic Significance. JAMA Ophthalmology, 2006, 124, 807.	2.6	9
288	Consequences of Verteporfin Photodynamic Therapy on Choroidal Neovascular Membranes. JAMA Ophthalmology, 2006, 124, 815.	2.6	39
289	Photodynamic Therapy in Retinal Angiomatous Proliferation Stage I. European Journal of Ophthalmology, 2006, 16, 326-329.	0.7	26
290	Verteporfin Therapy and Triamcinolone Acetonide: Convergent Modes of Action for Treatment of Neovascular Age-Related Macular Degeneration. European Journal of Ophthalmology, 2006, 16, 824-834.	0.7	12
291	Occult With No Classic Subfoveal Choroidal Neovascular Lesions in Age-Related Macular Degeneration. JAMA Ophthalmology, 2006, 124, 660.	2.6	29
292	Is There any Relationship between Photodynamic Therapy for Exudative Age-Related Macular Degeneration and Choroidal Neovascularization Recurrence? A Rationale for Combined Treatments. European Journal of Ophthalmology, 2006, 16, 686-694.	0.7	2
294	Evolution of Retinal Pigment Epithelium Detachment after Photodynamic Therapy for Choroidal Neovascularization in Age-Related Macular Degeneration. European Journal of Ophthalmology, 2006, 16, 491-494.	0.7	4

#	ARTICLE	IF	CITATIONS
295	A Review of Developments in the Management of Retinal Diseases. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 125-127.	1.1	6
296	MACULAR DEGENERATION: THE LATEST IN CURRENT SURGICAL MANAGEMENT. <i>Retina</i> , 2006, 26, S21-S25.	1.0	1
297	Retinal Angiomatous Proliferation Treated with a Combination of Intravitreal Triamcinolone Acetonide and Photodynamic Therapy with Verteporfin. <i>European Journal of Ophthalmology</i> , 2006, 16, 705-710.	0.7	14
299	INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2006, 26, 383-390.	1.0	278
300	MACULAR DEGENERATION: THE LATEST IN CURRENT SURGICAL MANAGEMENT. <i>Retina</i> , 2006, 26, S21-S25.	1.0	2
301	Successful Treatment of Retinal Angiomatous Proliferation by Photodynamic Therapy. <i>Optometry and Vision Science</i> , 2006, 83, 546-549.	0.6	7
302	ONE-YEAR RESULTS OF A PILOT STUDY USING ORAL 13-CIS RETINOIC ACID AS A TREATMENT FOR SUBFOVEAL PREDOMINANTLY OCCULT CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2006, 26, 314-321.	1.0	9
303	VERTEPORFIN PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH TOXOPLASMIC RETINOCHOROIDITIS. <i>Retina</i> , 2006, 26, 396-403.	1.0	46
304	ANECORTAVE ACETATE TREATMENT FOR RETINAL ANGIOMATOUS PROLIFERATION. <i>Retina</i> , 2006, 26, 773-779.	1.0	23
305	INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2006, 26, 383-390.	1.0	603
306	GLUTAMATE LEVELS IN AQUEOUS HUMOR OF PATIENTS WITH RETINAL ARTERY OCCLUSION. <i>Retina</i> , 2006, 26, 432-436.	1.0	49
307	COMBINED PHOTODYNAMIC THERAPY WITH VERTEPORFIN AND INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2006, 26, 988-993.	1.0	112
308	SELF-REPORTED ACUTE DECREASE IN VISUAL ACUITY AFTER PHOTODYNAMIC THERAPY FOR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2006, 26, 1042-1048.	1.0	11
309	Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization. <i>Acta Ophthalmologica</i> , 2006, 84, 743-748.	0.4	19
310	New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. <i>Acta Ophthalmologica</i> , 2006, 85, 6-20.	0.4	13
311	From basic to clinical research: a journey with the retina, the retinal pigment epithelium, the cornea, age-related macular degeneration and hereditary degenerations, as seen in the rear view mirror. <i>Acta Ophthalmologica</i> , 2006, 84, 452-465.	0.4	4
312	Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2006, 84, 831-833.	0.4	14
313	Does lesion size determine the success rate of photodynamic therapy for age-related macular degeneration?. <i>Eye</i> , 2006, 20, 43-45.	1.1	12

#	ARTICLE	IF	CITATIONS
314	Exudative retinal detachment after photodynamic therapy: a case report in an Asian patient. <i>Eye</i> , 2006, 20, 499-502.	1.1	6
315	Screening for age-related macular degeneration using nonstereo digital fundus photographs. <i>Eye</i> , 2006, 20, 471-475.	1.1	26
316	Review of first year result of photodynamic therapy on age-related macular degeneration in chinese population. <i>Eye</i> , 2006, 20, 523-526.	1.1	16
317	Low power vs standard power transpupillary thermotherapy in patients with age-related macular degeneration and subfoveal choroidal neovascularization ineligible for photodynamic therapy. <i>Eye</i> , 2006, 20, 649-654.	1.1	4
318	Photodynamic Therapy in Macular Diseases of Asian Populations: When East Meets West. <i>Japanese Journal of Ophthalmology</i> , 2006, 50, 161-169.	0.9	39
319	Polypoidal Choroidal Vasculopathy and Retinochoroidal Anastomosis in Japanese Patients Eligible for Photodynamic Therapy for Exudative Age-Related Macular Degeneration. <i>Japanese Journal of Ophthalmology</i> , 2006, 50, 354-360.	0.9	26
320	Verteporfin Therapy for Neovascular Age-Related Macular Degeneration in Indian Eyes. <i>Japanese Journal of Ophthalmology</i> , 2006, 50, 524-528.	0.9	5
321	One-year outcomes after photodynamic therapy in patients with age-related macular degeneration with poor baseline visual acuity. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 244, 1026-1028.	1.0	2
322	Photodynamic therapy with verteporfin for retinal angiomatous proliferation. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 244, 1224-1232.	1.0	44
323	Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 244, 1262-1266.	1.0	4
324	Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 245, 68-73.	1.0	112
325	Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System. <i>Journal of NeuroImmune Pharmacology</i> , 2006, 1, 340-350.	2.1	222
326	Visual function following transpupillary thermotherapy with adjusted laser parameters for the treatment of exudative age-related macular degeneration: a pilot study. <i>Clinical and Experimental Ophthalmology</i> , 2006, 34, 226-232.	1.3	4
327	Perspectives on Verteporfin Therapy Combined With Intravitreal Corticosteroids. <i>JAMA Ophthalmology</i> , 2006, 124, 561.	2.6	12
328	Visual Function in Patients With Choroidal Neovascularization Resulting From Age-Related Macular Degeneration: The Importance of Looking Beyond Visual Acuity. <i>Optometry and Vision Science</i> , 2006, 83, 178-189.	0.6	49
329	Photodynamic therapy in macular diseases. <i>Expert Review of Ophthalmology</i> , 2006, 1, 97-112.	0.3	1
330	Repeated Intravitreal Injection of Triamcinolone for Exudative Age-Related Macular Degeneration. <i>Ophthalmic Research</i> , 2006, 38, 324-328.	1.0	7
331	A review of developments in the management of retinal diseases. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 125-127.	1.1	4

#	ARTICLE	IF	CITATIONS
332	In vitro studies of the efficiency of two-photon activation of photodynamic therapy agents. , 2006, , .		4
334	Sequenced Combined Intravitreal Triamcinolone and Indocyanine Green Angiographyâ€“Guided Photodynamic Therapy for Retinal Angiomatous Proliferation. JAMA Ophthalmology, 2006, 124, 487.	2.6	74
335	Evolving European guidance on the medical management of neovascular age related macular degeneration. British Journal of Ophthalmology, 2006, 90, 1188-1196.	2.1	62
336	Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy. British Journal of Ophthalmology, 2006, 90, 1524-1530.	2.1	16
337	Phase I clinical trial results of verteporfin enhanced feeder vessel therapy in subfoveal choroidal neovascularisation in age related macular degeneration. British Journal of Ophthalmology, 2006, 90, 1152-1156.	2.1	12
338	The Proteome of Central and Peripheral Retina with Progression of Age-Related Macular Degeneration. , 2006, 47, 2280.		97
339	Long term results after transpupillary thermotherapy in eyes with occult choroidal neovascularisation associated with age related macular degeneration: a prospective trial. British Journal of Ophthalmology, 2006, 90, 158-161.	2.1	13
340	A 76-Year-Old Man With Macular Degeneration. JAMA - Journal of the American Medical Association, 2006, 295, 2394.	3.8	13
341	Should Corticosteroids Be Considered as Part of the Standard Care With Photodynamic Therapy?. JAMA Ophthalmology, 2006, 124, 563.	2.6	16
342	Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. British Journal of Ophthalmology, 2006, 90, 337-341.	2.1	72
343	Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes. British Journal of Ophthalmology, 2006, 90, 1034-1039.	2.1	23
344	Emerging drugs for age-related macular degeneration. Expert Opinion on Emerging Drugs, 2006, 11, 725-740.	1.0	16
345	A Novel Vascular Endothelial Growth Factor Receptor 2 Inhibitor, SU11248, Suppresses Choroidal Neovascularization In Vivo. Journal of Ocular Pharmacology and Therapeutics, 2006, 22, 213-218.	0.6	43
346	Therapy with Ribozyme to the Proliferating Cell Nuclear Antigen-Ribozyme and 5-Fluorouracil of Experimental Choroidal Neovascularization in Rats. Journal of Ocular Pharmacology and Therapeutics, 2006, 22, 1-9.	0.6	0
347	Anecortave acetate in the treatment of age-related macular degeneration. Expert Review of Ophthalmology, 2006, 1, 135-139.	0.3	0
348	Evaluation of Subretinal Triamcinolone Acetonide in Patients with Exudative Age-Related Macular Degeneration. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 46-53.	0.6	5
349	Laser photocoagulation for neovascular age-related macular degeneration. The Cochrane Library, 2007, , CD004763.	1.5	46
350	Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration. British Journal of Ophthalmology, 2007, 91, 753-756.	2.1	13

#	ARTICLE	IF	CITATIONS
351	Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy. <i>British Journal of Ophthalmology</i> , 2007, 91, 1183-1189.	2.1	29
352	Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro. <i>British Journal of Ophthalmology</i> , 2007, 91, 100-104.	2.1	17
353	Photodynamic therapy in the anti-VEGF era. <i>British Journal of Ophthalmology</i> , 2007, 91, 707-708.	2.1	5
354	Gamma Knife Radiosurgery in the Treatment of Choroidal Neovascularization (Wet-Type Macular) Tj ETQq1 1 0.784314 rgBT /Overloc	0.8	6
355	Efficacy of Photodynamic Therapy in the Management of Occult Choroidal Neovascularization Associated with Serous Pigment Epithelium Detachment. <i>Ophthalmologica</i> , 2007, 221, 313-319.	1.0	9
356	Emerging Therapies for Neovascular Age-Related Macular Degeneration: State of the Art. <i>Ophthalmologica</i> , 2007, 221, 366-377.	1.0	19
357	Ocular Photodynamic Therapy â€œ Standard Applications and New Indications (Part 1). <i>Ophthalmologica</i> , 2007, 221, 216-226.	1.0	40
358	Polypoidal choroidal vasculopathy. <i>British Journal of Ophthalmology</i> , 2007, 91, 1104-1105.	2.1	1
359	Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2007, 91, 1173-1176.	2.1	109
360	Neurotrophic Factors Minimize the Retinal Toxicity of Verteporfin Photodynamic Therapy. , 2007, 48, 430.		26
361	Polypoidal choroidal vasculopathy with an appearance similar to classic choroidal neovascularisation on fluorescein angiography. <i>British Journal of Ophthalmology</i> , 2007, 91, 1103-1104.	2.1	10
362	Autologous retinal pigment epithelium-choroid sheet transplantation in age related macular degeneration: morphological and functional results. <i>British Journal of Ophthalmology</i> , 2007, 91, 349-353.	2.1	54
363	Beta Carotene Supplementation and Age-Related Maculopathy in a Randomized Trial of US Physicians. <i>JAMA Ophthalmology</i> , 2007, 125, 333.	2.6	35
364	The 100 Most Frequently Cited Articles in Ophthalmology Journals. <i>JAMA Ophthalmology</i> , 2007, 125, 952.	2.6	91
365	VARIABILITY AMONG RETINA SPECIALISTS IN EVALUATING FLUORESCEIN ANGIOGRAMS OF PATIENTS WITH NEOVASCULAR AGERELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 798-803.	1.0	9
366	INFLUENCE OF VERTEPORFIN PHOTODYNAMIC THERAPY ON INFLAMMATION IN HUMAN CHOROIDAL NEOVASCULAR MEMBRANES SECONDARY TO AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 713-723.	1.0	32
367	TEARS OF THE RETINAL PIGMENT EPITHELIUM. <i>Retina</i> , 2007, 27, 523-534.	1.0	156
368	TREATMENT OF NAÏVE LESIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB. <i>Retina</i> , 2007, 27, 851-856.	1.0	23

#	ARTICLE	IF	CITATIONS
369	HEMORRHAGIC COMPLICATIONS AFTER PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. <i>Retina</i> , 2007, 27, 335-341.	1.0	152
370	TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 133-140.	1.0	194
371	SELECTIVE PHOTODYNAMIC THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH POLYPOIDAL CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2007, 27, 825-831.	1.0	74
372	INTRAVITREAL BEVACIZUMAB COMBINED WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF OCCULT CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH SEROUS PIGMENT EPITHELIUM DETACHMENT IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 891-896.	1.0	36
373	Photodynamic Therapy and Combination Treatments. <i>International Ophthalmology Clinics</i> , 2007, 47, 95-115.	0.3	7
374	PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR SERPIGINOUS CHOROIDITIS WITH SUBFOVEAL CHOROIDAL NEOVASCULARIZATION. <i>Retinal Cases and Brief Reports</i> , 2007, 1, 3-4.	0.3	1
375	RPE TEARS AFTER PEGAPTANIB TREATMENT IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 857-863.	1.0	61
376	Ranibizumab in the treatment of age-related macular degeneration. <i>Aging Health</i> , 2007, 3, 9-14.	0.3	0
377	Advances in AMD Imaging. <i>International Ophthalmology Clinics</i> , 2007, 47, 65-74.	0.3	6
378	PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH RETINAL PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 342-348.	1.0	21
379	Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 1039-1046.	0.7	38
380	EFFECT OF ADJUNCTIVE DICLOFENAC WITH VERTEPORFIN THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 693-700.	1.0	9
381	Value-based medicine and interventions for macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2007, 18, 194-200.	1.3	9
382	Intravitreal Bevacizumab for Subfoveal Idiopathic Choroidal Neovascularization. <i>JAMA Ophthalmology</i> , 2007, 125, 1487.	2.6	51
383	Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration—A Review of Clinical Outcomes. <i>Survey of Ophthalmology</i> , 2007, 52, S79-S90.	1.7	35
384	Retinal Pigment Epithelial Detachment. <i>Survey of Ophthalmology</i> , 2007, 52, 227-243.	1.7	128
385	Is Significant Relevant? Validity and Patient Benefit of Randomized Controlled Clinical Trials on Age-related Macular Degeneration. <i>Survey of Ophthalmology</i> , 2007, 52, 266-278.	1.7	4
386	Use of Fundus Imaging in Quantification of Age-related Macular Change. <i>Survey of Ophthalmology</i> , 2007, 52, 655-671.	1.7	59

#	ARTICLE	IF	CITATIONS
387	Relative Cost of a Line of Vision in Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2007, 114, 847-854.	2.5	40
388	Cost-effectiveness of Vitamin Therapy for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2007, 114, 1319-1326.	2.5	39
389	Triamcinolone Acetonide as Adjunctive Treatment to Verteporfin in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2007, 114, 2183-2189.	2.5	38
390	Verteporfin Therapy and Intravitreal Bevacizumab Combined and Alone in Choroidal Neovascularization due to Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2007, 114, 1179-1185.	2.5	134
391	Periocular Triamcinolone and Photodynamic Therapy for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2007, 114, 1713-1721.e1.	2.5	14
392	Visual Acuity as an Outcome Measure in Clinical Trials of Retinal Diseases. <i>Ophthalmology</i> , 2007, 114, 1804-1809.	2.5	142
393	Photodynamic Therapy for Nonsubfoveal Choroidal Neovascularization in 100 Eyes With Pathologic Myopia. <i>American Journal of Ophthalmology</i> , 2007, 143, 77-82.e2.	1.7	22
394	Anatomical and Visual Outcome of Retinal Angiomatous Proliferation Treated with Photodynamic Therapy and Intravitreal Triamcinolone. <i>American Journal of Ophthalmology</i> , 2007, 143, 701-704.	1.7	18
395	Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday Patients. <i>American Journal of Ophthalmology</i> , 2007, 144, 627-637.e2.	1.7	210
396	Verteporfin Therapy of Subfoveal Occult Choroidal Neovascularization in AMD Using Delayed Light Application: One-year Results of the VALIO Study. <i>American Journal of Ophthalmology</i> , 2007, 144, 970-972.e4.	1.7	8
397	Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. <i>Current Medical Research and Opinion</i> , 2007, 23, 477-487.	0.9	52
398	Combination Therapy for Choroidal Neovascularisation. <i>Drugs and Aging</i> , 2007, 24, 979-990.	1.3	18
399	Handbook of Nutrition and Ophthalmology. , 2007, , .		14
400	Photodynamic therapy for neovascular age-related macular degeneration. <i>The Cochrane Library</i> , 2007, , CD002030.	1.5	77
401	Pegaptanib sodium for the treatment of ocular vascular disease. <i>Expert Review of Ophthalmology</i> , 2007, 2, 45-60.	0.3	1
406	Zinc Phthalocyanine Tetrasulfonate (ZnPc <sub>4</sub> ): A New Photosensitizer for Photodynamic Therapy in Choroidal Neovascularization. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2007, 23, 377-386.	0.6	21
407	Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration. <i>Core Evidence</i> , 2007, .	4.7	5
408	Serous Retinal Detachment in Patients with Choroidal Neovascularization Following Photodynamic Therapy. <i>Journal of Korean Ophthalmological Society</i> , 2007, 48, 1354.	0.0	1

#	ARTICLE	IF	CITATIONS
410	Synergies of VEGF Inhibition and Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration. , 2007, 48, 1767.		34
411	Reduced Photoreceptor Damage after Photodynamic Therapy through Blockade of Nitric Oxide Synthase in a Model of Choroidal Neovascularization. , 2007, 48, 2268.		21
412	Retinal Capillary Hemangioma Treated with Verteporfin Photodynamic Therapy and Intravitreal Triamcinolone Acetonide. Korean Journal of Ophthalmology: KJO, 2007, 21, 178.	0.5	10
413	The Diagnostic Contribution of Indocyanine Green to Fluorescein Angiography in Fellow Drusen Eyes of Patients with Wet Age-Related Macular Degeneration. European Journal of Ophthalmology, 2007, 17, 615-619.	0.7	9
414	The Nature and Frequency of Neovascular Age-Related Macular Degeneration. European Journal of Ophthalmology, 2007, 17, 75-83.	0.7	17
415	Correlation between Focal Macular Electroretinograms and Angiographic Findings after Photodynamic Therapy. , 2007, 48, 2254.		27
416	Treatment of Exudative Age-Related Macular Degeneration. Journal of the Korean Medical Association, 2007, 50, 731.	0.1	1
417	The Effect of Complement Factor H Y402H Polymorphism on the Outcome of Photodynamic Therapy in Age-related Macular Degeneration. European Journal of Ophthalmology, 2007, 17, 943-949.	0.7	46
418	Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmology, 2007, 7, 10.	0.6	38
419	Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Eye, 2007, 21, 387-394.	1.1	13
420	Transpupillary thermotherapy for the treatment of choroidal neovascularization in age-related macular degeneration in Taiwan. Eye, 2007, 21, 721-726.	1.1	4
421	Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration. Eye, 2007, 21, 1455-1463.	1.1	28
422	Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmologica, 2007, 85, 486-494.	0.4	45
423	Ranibizumab for the treatment of neovascular AMD. International Journal of Clinical Practice, 2007, 61, 501-509.	0.8	21
424	Surgical treatment of age-related macular degeneration: will there be a role in the future?. Clinical and Experimental Ophthalmology, 2007, 35, 070130044246010-???.	1.3	1
425	Photodynamic therapy with verteporfin for choroidal neovascularization due to age-related macular degeneration and other causes: a New Zealand outcomes study. Clinical and Experimental Ophthalmology, 2007, 35, 24-31.	1.3	12
426	Factors influencing poor visual outcome in patients treated with photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration. Clinical and Experimental Ophthalmology, 2007, 35, 330-334.	1.3	5
427	New algorithm for assessing patient suitability for macular translocation surgery. Clinical and Experimental Ophthalmology, 2007, 35, 448-457.	1.3	12

#	ARTICLE	IF	CITATIONS
428	Management of neovascular age-related macular degeneration. <i>Progress in Retinal and Eye Research</i> , 2007, 26, 437-451.	7.3	79
429	Optical Coherence Tomography Findings Following Photodynamic Therapy of Idiopathic Subfoveal Choroidal Neovascularization. <i>Annals of Ophthalmology</i> , 2007, 39, 232-236.	0.0	1
431	Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. <i>Documenta Ophthalmologica</i> , 2007, 114, 37-44.	1.0	45
432	Determinants of Patient Satisfaction with Photodynamic Therapy for Neovascular Age-related Macular Degeneration or Polypoidal Choroidal Vasculopathy. <i>Japanese Journal of Ophthalmology</i> , 2007, 51, 368-374.	0.9	6
433	Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 215-220.	1.0	34
434	Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1085-1095.	1.0	31
435	Chorioretinal anastomosis and photodynamic therapy: a two-year follow-up study. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1131-1139.	1.0	25
436	Retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration: long-term results. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1681-1689.	1.0	66
437	Combined photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: effect of initial visual acuity on treatment response. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1667-1672.	1.0	6
438	Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 246, 81-87.	1.0	401
439	The end of submacular surgery for age-related macular degeneration? A meta-analysis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 490-501.	1.0	28
440	Photodynamic therapy combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. <i>Frontiers of Medicine in China</i> , 2007, 1, 405-409.	0.1	1
442	Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD): Results of the Japanese AMD Trial (JAT) extension. <i>Japanese Journal of Ophthalmology</i> , 2008, 52, 99-107.	0.9	15
443	Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy. <i>Japanese Journal of Ophthalmology</i> , 2008, 52, 457-462.	0.9	24
444	Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne®), in the CAM model. <i>Angiogenesis</i> , 2008, 11, 235-243.	3.7	43
445	A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. <i>Trials</i> , 2008, 9, 56.	0.7	31
446	Photodynamic therapy as treatment of chronic idiopathic central serous chorioretinopathy. <i>Lasers in Surgery and Medicine</i> , 2008, 40, 671-675.	1.1	28
447	The Royal College of Ophthalmologists interim recommendations for the management of patients with age-related macular degeneration. <i>Eye</i> , 2008, 22, 864-868.	1.1	16

#	ARTICLE	IF	CITATIONS
448	Comparison of visual acuity outcomes in predominantly classic vs occult lesions in age-related macular degeneration treated with photodynamic therapy. <i>Eye</i> , 2008, 22, 194-199.	1.1	11
449	The introduction of verteporfin photodynamic therapy in the UK: PDT users group (PDTUG) surveillance programme report 1. <i>Eye</i> , 2008, 22, 671-677.	1.1	2
450	Optical coherence tomography on autologous translocation of choroid and retinal pigment epithelium in age-related macular degeneration. <i>Eye</i> , 2008, 22, 782-789.	1.1	8
451	The effect of photodynamic therapy on retrobulbar blood flow parameters. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 39-42.	1.3	4
453	Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results. <i>American Journal of Ophthalmology</i> , 2008, 145, 862-874.e3.	1.7	181
454	The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2008, 115, 116-126.e1.	2.5	505
455	Characteristics of Choroidal Neovascularization in the Complications of Age-Related Macular Degeneration Prevention Trial. <i>Ophthalmology</i> , 2008, 115, 1468-1473.e2.	2.5	12
456	Use of fluorescein and indocyanine green angiography in polypoidal choroidal vasculopathy patients following photodynamic therapy. <i>Canadian Journal of Ophthalmology</i> , 2008, 43, 678-682.	0.4	9
457	Pharmacotherapy of age-related macular degeneration. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 3045-3052.	0.9	10
458	Carotenoids and Co-Antioxidants in Age-Related Maculopathy: Design and Methods. <i>Ophthalmic Epidemiology</i> , 2008, 15, 389-401.	0.8	37
459	Identification of a Novel Vascular Endothelial Growth Factor Receptor 2 Inhibitor and Its Effect for Choroidal Neovascularization <i>In Vivo</i> . <i>Current Eye Research</i> , 2008, 33, 1002-1010.	0.7	23
460	Combination of Photodynamic Therapy and Intraocular Triamcinolone for Exudative Age-Related Macular Degeneration and Long-Term Chorioretinal Macular Atrophy. <i>JAMA Ophthalmology</i> , 2008, 126, 1367.	2.6	24
461	A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2008, 92, 757-761.	2.1	11
462	Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study. <i>British Journal of Ophthalmology</i> , 2008, 92, 1620-1627.	2.1	26
463	Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. <i>British Journal of Ophthalmology</i> , 2008, 92, 1642-1647.	2.1	50
464	Early Clinical Experience with Ranibizumab for Occult and Minimally Classic Neovascular Membranes in Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2008, 222, 321-323.	1.0	18
465	Transpupillary Thermotherapy in Chinese Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: Emphasis on the Influence of Power Setting. <i>Ophthalmologica</i> , 2008, 222, 117-122.	1.0	1
466	Pharmacotherapy for the Treatment of Choroidal Neovascularization Due to Age-Related Macular Degeneration. <i>Annual Review of Pharmacology and Toxicology</i> , 2008, 48, 61-78.	4.2	34

#	ARTICLE	IF	CITATIONS
467	Age-related macular degeneration: diagnosis and management. British Medical Bulletin, 2008, 85, 127-149.	2.7	93
468	Identifying Research Priorities: The Value of Information Associated with Repeat Screening for Age-Related Macular Degeneration. Medical Decision Making, 2008, 28, 33-43.	1.2	25
469	Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. British Journal of Ophthalmology, 2008, 92, 1628-1635.	2.1	39
472	Verteporfin photodynamic therapy in the age of antiangiogenic therapy. Expert Review of Ophthalmology, 2008, 3, 365-383.	0.3	1
473	Early Effects of Triamcinolone on Vascular Endothelial Growth Factor and Endostatin in Human Choroidal Neovascularization. JAMA Ophthalmology, 2008, 126, 193.	2.6	11
474	12-MONTH RETROSPECTIVE STUDY AND REVIEW OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2008, 29, 289-297.	1.0	16
475	COMBINATION PHOTODYNAMIC THERAPY AND INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN A NORTH INDIAN POPULATION. Retina, 2008, 28, 1296-1301.	1.0	4
476	AGREEMENT AMONG CANADIAN RETINA SPECIALISTS IN THE DETERMINATION OF TREATMENT ELIGIBILITY FOR PHOTODYNAMIC THERAPY IN AGE-RELATED MACULAR DEGENERATION. Retina, 2008, 28, 1421-1426.	1.0	8
477	COMBINED PHOTODYNAMIC THERAPY AND INTRAVITREAL TRIAMCINOLONE FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PUNCTATE INNER CHOROIDOPATHY OR OF IDIOPATHIC ORIGIN. Retina, 2008, 28, 71-80.	1.0	45
478	The cost of vision for vitreoretinal interventions. Current Opinion in Ophthalmology, 2008, 19, 195-201.	1.3	2
479	COMBINATION PHOTODYNAMIC THERAPY AND INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AMD IN A NORTH INDIAN POPULATION. Retina, 2008, 28, 1132-1137.	1.0	10
480	INTRAVITREAL INJECTION OF BEVACIZUMAB COMBINED WITH VERTEPORFIN PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2008, 28, 675-681.	1.0	44
481	Photoreceptor Protection after Photodynamic Therapy Using Dexamethasone in a Rat Model of Choroidal Neovascularization. , 2008, 49, 5008.		17
482	Angioid streaks, clinical course, complications, and current therapeutic management. Therapeutics and Clinical Risk Management, 0, , 81.	0.9	7
483	Long-term Effect of Intravitreal Bevacizumab for CNV Secondary to Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2008, 49, 1935.	0.0	9
484	Is reduction in the risk of vision loss the only benefit of photodynamic therapy in predominantly classic subfoveal choroidal neovascularization?. Clinical Ophthalmology, 2008, 2, 773.	0.9	0
485	The Efficacy of Verteporfin Photodynamic Therapy in Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2008, 49, 274.	0.0	0
486	Single-Session Photodynamic Therapy Combined with Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration. European Journal of Ophthalmology, 2008, 18, 297-300.	0.7	19

#	ARTICLE	IF	CITATIONS
487	Retinal Pigment Epithelial Marginal Retraction after Photodynamic Therapy for Choroidal Neovascularization in Pathologic Myopia. <i>European Journal of Ophthalmology</i> , 2008, 18, 841-844.	0.7	1
488	Transcutaneous Electrical Retinal Stimulation Therapy for Age-Related Macular Degeneration. <i>Open Ophthalmology Journal</i> , 2008, 2, 132-136.	0.1	26
489	Photodynamic Therapy Treatment for Eyes with Drusenoid Pigment Epithelium Detachment. <i>Korean Journal of Ophthalmology: KJO</i> , 2008, 22, 194.	0.5	8
490	Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization. , 2008, 49, 662.		20
491	Verteporfin Photodynamic Therapy for Subfoveal Choroidal Neovascularization in Pathologic Myopia: A 12-Month Retrospective Review. <i>European Journal of Ophthalmology</i> , 2008, 18, 955-959.	0.7	7
492	Treatment of neovascular age-related macular degeneration: Current therapies. <i>Clinical Ophthalmology</i> , 2009, 3, 175.	0.9	28
493	The Efficacy of Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration. <i>Journal of Korean Ophthalmological Society</i> , 2009, 50, 725.	0.0	9
494	Changes of Choroidal Perfusion in Indocyanine Green Angiography After Photodynamic Therapy for Choroidal Neovascularization. <i>Journal of Korean Ophthalmological Society</i> , 2009, 50, 69.	0.0	0
495	Age-related macular degeneration: current treatments. <i>Clinical Ophthalmology</i> , 2009, 3, 155.	0.9	43
496	Changes in visual function and thickness of macula after photodynamic therapy for age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2009, 3, 483.	0.9	18
497	Exudative Age-Related Macular Degeneration: Current Therapies and Potential Treatments. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2225.	0.1	0
498	Joint Assessment of Intended and Unintended Effects of Medications: An Example Using Vascular Endothelial Growth Factor Inhibitors for Neovascular Age-Related Macular Degeneration. <i>Journal of Ophthalmology</i> , 2009, 2009, 1-9.	0.6	0
499	Autologous Transplantation of Retinal Pigment Epitheliumâ€“Bruchâ€™s Membrane Complex for Hemorrhagic Age-Related Macular Degeneration. , 2009, 50, 2975.		43
500	Inflammation and the pathogenesis of age-related macular degeneration. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 641-651.	1.5	72
501	Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. <i>Current Medical Research and Opinion</i> , 2009, 25, 1853-1860.	0.9	25
502	Improved Vision-Related Function After Ranibizumab vs Photodynamic Therapy. <i>JAMA Ophthalmology</i> , 2009, 127, 13.	2.6	93
503	Folic Acid, Pyridoxine, and Cyanocobalamin Combination Treatment and Age-Related Macular Degeneration in Women. <i>Archives of Internal Medicine</i> , 2009, 169, 335.	4.3	145
504	Risk Factors for Retinal Hemorrhage after Photodynamic Therapy in Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2009, 223, 78-84.	1.0	9

#	ARTICLE	IF	CITATIONS
505	Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. <i>British Journal of Ophthalmology</i> , 2009, 93, 754-758.	2.1	47
506	Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. <i>Pharmacogenomics</i> , 2009, 10, 81-95.	0.6	25
508	Comparative Assessment of Photodynamic Therapy for Typical Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A Multicenter Study in Hyogo Prefecture, Japan. <i>Ophthalmologica</i> , 2009, 223, 333-338.	1.0	44
509	Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study. <i>British Journal of Ophthalmology</i> , 2009, 93, 914-919.	2.1	16
510	Forecasting Age-Related Macular Degeneration Through the Year 2050. <i>JAMA Ophthalmology</i> , 2009, 127, 533.	2.6	292
511	One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 899-906.	1.0	31
512	Effect of combined treatment with sub-Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age-related macular degeneration. <i>Japanese Journal of Ophthalmology</i> , 2009, 53, 512-518.	0.9	9
513	Photodynamic therapy for polypoidal choroidal vasculopathy: Baseline perimetric results and visual outcomes. <i>Japanese Journal of Ophthalmology</i> , 2009, 53, 588-592.	0.9	6
514	Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: A 30-month multicenter study in Hyogo, Japan. <i>Japanese Journal of Ophthalmology</i> , 2009, 53, 593-597.	0.9	39
515	Early OCT changes of neuroretinal foveal thickness after first versus repeated PDT in AMD. <i>International Ophthalmology</i> , 2009, 29, 1-5.	0.6	3
516	Pattern electroretinographic results after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. <i>Documenta Ophthalmologica</i> , 2009, 119, 37-42.	1.0	4
517	Bevacizumab: a new hope?. <i>Eye</i> , 2009, 23, 1755-1757.	1.1	0
518	Verteporfin therapy in occult with no classic CNV due to AMD: results of the Photodynamic Therapy in Occult-Only Lesions study. <i>Eye</i> , 2009, 23, 791-800.	1.1	1
519	Photodynamic therapy combined with posterior subtenon triamcinolone acetonide injection in the treatment of choroidal neovascularization. <i>Eye</i> , 2009, 23, 645-651.	1.1	8
520	Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. <i>Eye</i> , 2009, 23, 2163-2168.	1.1	70
521	Treatment of recurrent retinal angiomatous proliferation with intravitreal triamcinolone acetonide followed by photodynamic therapy with verteporfin: A retrospective case series. <i>Current Therapeutic Research</i> , 2009, 70, 240-251.	0.5	0
522	Psychophysical Function in Age-related Maculopathy. <i>Survey of Ophthalmology</i> , 2009, 54, 167-210.	1.7	86
523	Applying the CONSORT and STROBE Statements to Evaluate the Reporting Quality of Neovascular Age-related Macular Degeneration Studies. <i>Ophthalmology</i> , 2009, 116, 286-296.e4.	2.5	70

#	ARTICLE	IF	CITATIONS
524	Economic Implications of Current Age-Related Macular Degeneration Treatments. <i>Ophthalmology</i> , 2009, 116, 481-487.	2.5	27
525	Verteporfin Photodynamic Therapy Combined With Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, 747-755.e1.	2.5	83
526	Natural History of Predominantly Classic, Minimally Classic, and Occult Subgroups in Exudative Age-related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, 1901-1907.	2.5	38
527	Introduction: Understanding the Role of Angiogenesis and Antiangiogenic Agents in Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, S1-S7.	2.5	166
528	Outcome Measures to Assess Efficacy of Treatments for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, S8-S14.	2.5	6
529	Evaluation of Actual vs Expected Photodynamic Therapy Spot Size. <i>American Journal of Ophthalmology</i> , 2009, 147, 859-864.e1.	1.7	2
530	Association between Foveal Photoreceptor Integrity and Visual Outcome in Neovascular Age-related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2009, 148, 83-89.e1.	1.7	102
531	Current and future therapies for age-related macular degeneration. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 341-362.	1.0	9
532	Confocal Scanning Laser Tomography Analysis of Choroidal Neovascularization and Correlation with Quantitative Fluorescein Angiography. <i>Current Eye Research</i> , 2009, 34, 319-327.	0.7	2
533	Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. <i>Acta Ophthalmologica</i> , 2009, 87, 118-132.	0.6	76
534	RETINAL PIGMENT EPITHELIAL TEARS IN RANIBIZUMAB-TREATED EYES. <i>Retina</i> , 2009, 29, 335-339.	1.0	63
535	VERTEPORFIN COMBINATION REGIMENS IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 133-148.	1.0	30
536	TWELVE-MONTH SAFETY AND VISUAL ACUITY RESULTS FROM A FEASIBILITY STUDY OF INTRAOCULAR, EPIRETINAL RADIATION THERAPY FOR THE TREATMENT OF SUBFOVEAL CNV SECONDARY TO AMD. <i>Retina</i> , 2009, 29, 157-169.	1.0	56
537	RETROSPECTIVE REVIEW OF THE EFFICACY OF TOPICAL BROMFENAC (0.09%) AS AN ADJUNCTIVE THERAPY FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 1527-1531.	1.0	25
538	INTRAVITREAL BEVACIZUMAB FOR TREATMENT-NAÏVE PATIENTS WITH SUBFOVEAL OCCULT CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 1227-1234.	1.0	14
539	Visual Acuity Outcomes Among Sham vs No-Treatment Controls From Randomized Trials. <i>JAMA Ophthalmology</i> , 2009, 127, 725.	2.6	5
540	FOCAL MACULAR ELECTRORETINOGRAMS AFTER PHOTODYNAMIC THERAPY COMBINED WITH POSTERIOR JXTASCLERAL TRIAMCINOLONE ACETONIDE. <i>Retina</i> , 2009, 29, 803-810.	1.0	7
541	RETINAL ANGIOMATOUS PROLIFERATION. <i>Retina</i> , 2009, 29, 732-739.	1.0	75

#	ARTICLE	IF	CITATIONS
543	EFFECT OF PHOTODYNAMIC THERAPY ALONE OR COMBINED WITH POSTERIOR SUBTENON TRIAMCINOLONE ACETONIDE OR INTRAVITREAL BEVACIZUMAB ON CHOROIDAL HYPOFLUORESCENCE BY INDOCYANINE GREEN ANGIOGRAPHY. <i>Retina</i> , 2010, 30, 495-502.	1.0	17
544	Complement, Age-Related Macular Degeneration and a Vision of the Future. <i>JAMA Ophthalmology</i> , 2010, 128, 349.	2.6	147
546	Surgery for CNV and autologous choroidal RPE patch transplantation: exposing the submacular space. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 37-47.	1.0	46
547	Low-fluence-rate photodynamic therapy to treat subfoveal choroidal neovascularization in pathological myopia. A study of efficacy and safety. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 497-502.	1.0	5
548	A review of clinical trials of anti-VEGF agents for diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 915-930.	1.0	238
549	Intravitreal bevacizumab for age-related macular degeneration with good visual acuity. <i>Japanese Journal of Ophthalmology</i> , 2010, 54, 565-570.	0.9	14
550	Long-term control of choroidal neovascularization in quiescent congenital toxoplasma retinochoroiditis with photodynamic therapy: 4-year results. <i>International Ophthalmology</i> , 2010, 30, 51-56.	0.6	15
551	Photodynamic therapy for choroidal neovascularization in young adult patients. <i>International Ophthalmology</i> , 2010, 30, 345-351.	0.6	5
552	Current indications for ocular photodynamic therapy – A review of the literature and two case reports. <i>Medical Laser Application: International Journal for Laser Treatment and Research</i> , 2010, 25, 235-241.	0.4	2
553	Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. <i>Eye</i> , 2010, 24, 203-213.	1.1	23
554	Exudative AMD subtypes and eligibility for treatment with ranibizumab. <i>Eye</i> , 2010, 24, 1247-1251.	1.1	15
555	Retinal angiomatous proliferation or retinal anastomosis to the lesion. <i>Eye</i> , 2010, 24, 491-496.	1.1	36
556	Neovascular age-related macular degeneration: decision making and optimal management. <i>Eye</i> , 2010, 24, 497-505.	1.1	25
557	Effects of Photodynamic Therapy Using Hematoporphyrin Monomethyl Ether on Experimental Choroidal Neovascularization. <i>Photochemistry and Photobiology</i> , 2010, 86, 972-980.	1.3	5
558	Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. <i>Clinical Ophthalmology</i> , 2010, 4, 369.	0.9	20
559	Photosensitizers and photodynamic therapy verteporfin. , 2010, , 297-305.		2
560	Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up. <i>Clinical Ophthalmology</i> , 2010, 4, 1237.	0.9	12
561	Lucentis® using Visudyne® study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. <i>Clinical Ophthalmology</i> , 2010, 4, 1073.	0.9	18

#	ARTICLE	IF	CITATIONS
562	A Novel Haplotype with the R345W Mutation in the <i>EFEMP1</i> Gene Associated with Autosomal Dominant Drusen in a Japanese Family. , 2010, 51, 1643.		37
563	Update on combination therapy in wet age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 681-688.	0.3	1
564	Bevacizumab for neovascular age-related macular degeneration (ABC trial): multicenter randomized double-masked study. Expert Review of Clinical Pharmacology, 2010, 3, 747-752.	1.3	5
565	Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand?. British Journal of Ophthalmology, 2010, 94, 143-145.	2.1	17
566	Alternative anti-VEGF treatment regimens in exudative age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 799-809.	0.3	0
567	Neovascular age-related macular degeneration. , 2010, , 128-132.		3
568	Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration. JAMA Ophthalmology, 2010, 128, 1273.	2.6	181
569	Inflammatory Mediators and Angiogenic Factors in Choroidal Neovascularization: Pathogenetic Interactions and Therapeutic Implications. Mediators of Inflammation, 2010, 2010, 1-14.	1.4	170
571	Response to Ranibizumab Therapy in Neovascular AMD – An Evaluation of Good and Bad Responders. Klinische Monatsblätter Für Augenheilkunde, 2010, 227, 244-248.	0.3	26
572	Anti-VEGF agents for age-related macular degeneration. Expert Opinion on Therapeutic Patents, 2010, 20, 103-118.	2.4	31
574	Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 45, 36-40.	0.4	24
575	Development of novel drugs for ocular diseases: possibilities for individualized therapy. Personalized Medicine, 2010, 7, 371-386.	0.8	5
576	Chorioretinal Ischemia and Angiogenic Milieu Following Photodynamic Therapy. Current Eye Research, 2010, 35, 314-321.	0.7	7
577	Current treatment options for retinal angiomatous proliferans (RAP). British Journal of Ophthalmology, 2010, 94, 672-677.	2.1	29
578	Age-related macular degeneration: Current and novel therapies. Maturitas, 2010, 66, 46-50.	1.0	41
579	Vitamin E and Age-Related Macular Degeneration in a Randomized Trial of Women. Ophthalmology, 2010, 117, 1163-1168.	2.5	35
580	The Multicenter Uveitis Steroid Treatment Trial: Rationale, Design, and Baseline Characteristics. American Journal of Ophthalmology, 2010, 149, 550-561.e10.	1.7	179
581	Bevacizumab versus ranibizumab for the treatment of neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 603-615.	0.3	1

#	ARTICLE	IF	CITATIONS
582	The non-antibiotic properties of tetracyclines: Clinical potential in ophthalmic disease. <i>Pharmacological Research</i> , 2011, 64, 614-623.	3.1	66
583	Bevacizumab and Neovascular Age Related Macular Degeneration: Pathogenesis and Treatment. <i>Seminars in Ophthalmology</i> , 2011, 26, 69-76.	0.8	23
584	Drug Product Development for the Back of the Eye. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011, , .	0.2	13
585	Genetic Predictors of Response to Photodynamic Therapy. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 195-210.	1.6	9
586	Does Laser Still Have a Role in the Management of Retinal Vascular and Neovascular Diseases?. <i>American Journal of Ophthalmology</i> , 2011, 152, 332-339.e1.	1.7	55
587	Punctate Inner Choroidopathy. <i>Survey of Ophthalmology</i> , 2011, 56, 36-53.	1.7	59
588	Complement Factor H and High-Temperature Requirement A-1 Genotypes and Treatment Response of Age-related Macular Degeneration. <i>Ophthalmology</i> , 2011, 118, 93-100.	2.5	53
589	Characteristics of Patients Losing Vision after 2 Years of Monthly Dosing in the Phase III Ranibizumab Clinical Trials. <i>Ophthalmology</i> , 2011, 118, 523-530.	2.5	228
590	Genetic Variants in Pigment Epithelium-Derived Factor Influence Response of Polypoidal Choroidal Vasculopathy to Photodynamic Therapy. <i>Ophthalmology</i> , 2011, 118, 1408-1415.	2.5	24
591	Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2011, 89, 585-590.	0.6	7
592	Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. <i>Korean Journal of Ophthalmology: KJO</i> , 2011, 25, 231.	0.5	8
593	Regression of Peripapillary Choroidal Neovascularization after Oscillatory Transpupillary Thermotherapy and Anti-VEGF Pharmacotherapy. <i>European Journal of Ophthalmology</i> , 2011, 21, 162-172.	0.7	6
594	ASSOCIATION BETWEEN FOVEAL MICROSTRUCTURE AND VISUAL OUTCOME IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2011, 31, 1627-1636.	1.0	52
595	Is Indocyanine Green Angiography Still Relevant?. <i>Retina</i> , 2011, 31, 209-221.	1.0	25
596	Preferred therapies for neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2011, 22, 199-204.	1.3	36
597	Pharmacological Treatments for Neovascular Age-Related Macular Degeneration: Can Mixed Treatment Comparison Meta-Analysis be Useful?. <i>Current Drug Targets</i> , 2011, 12, 212-220.	1.0	5
598	Editorial [Hot Topic: Therapeutic Approaches for Vision Loss due to Choroidal Neovascularizations in Age Related Macular Degeneration (Guest Editor: Ciro Costagliola)]. <i>Current Drug Targets</i> , 2011, 12, 133-137.	1.0	0
599	Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration. <i>Current Drug Targets</i> , 2011, 12, 149-172.	1.0	56

#	ARTICLE	IF	CITATIONS
600	RANIBIZUMAB MONOTHERAPY VERSUS SINGLE-SESSION VERTEPORFIN PHOTODYNAMIC THERAPY COMBINED WITH AS-NEEDED RANIBIZUMAB TREATMENT FOR THE MANAGEMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2011, 31, 636-644.	1.0	20
601	Age-related macular degeneration: review of current treatments. <i>Expert Review of Ophthalmology</i> , 2011, 6, 195-201.	0.3	1
602	Pseudoxanthoma elasticum, ocular manifestations, complications and treatment. <i>Australasian journal of optometry, The</i> , 2011, 94, 169-180.	0.6	66
603	The Cost-Effectiveness of Three Screening Alternatives for People with Diabetes with No or Early Diabetic Retinopathy. <i>Health Services Research</i> , 2011, 46, 1534-1561.	1.0	47
604	Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 273-280.	1.0	9
605	Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy. <i>Japanese Journal of Ophthalmology</i> , 2011, 55, 241-247.	0.9	6
607	Emerging therapeutic approaches in the management of retinal angiogenesis and edema. <i>Journal of Molecular Medicine</i> , 2011, 89, 343-361.	1.7	25
608	Nonviral gene therapy for age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2011, 6, 81-93.	0.3	5
609	Genetic Association with Response to Intravitreal Ranibizumab in Patients with Neovascular AMD. , 2011, 52, 4694.		112
610	Quadruple Therapy Leads to a Sustained Improvement of Vision in Patients with Wet Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2011, 226, 45-50.	1.0	5
611	Dietary $\omega$ -3 Fatty Acid and Fish Intake and Incident Age-Related Macular Degeneration in Women. <i>JAMA Ophthalmology</i> , 2011, 129, 921.	2.6	120
612	Retinal Pigment Epithelial Detachments in Age-Related Macular Degeneration: Classification and Therapeutic Options. <i>Seminars in Ophthalmology</i> , 2011, 26, 198-208.	0.8	33
613	Challenges in the design and implementation of the Multicenter Uveitis Steroid Treatment (MUST) Trial â€” lessons for comparative effectiveness trials. <i>Clinical Trials</i> , 2011, 8, 736-743.	0.7	13
614	The past, present, and future of exudative age-related macular degeneration treatment. <i>Middle East African Journal of Ophthalmology</i> , 2012, 19, 43.	0.5	15
615	Antiangiogenic Therapy for Ischemic Retinopathies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006411-a006411.	2.9	63
616	Preferred therapies for neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2012, 23, 182-188.	1.3	43
617	TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY WITH PHOTODYNAMIC THERAPY. <i>Retina</i> , 2012, 32, 529-535.	1.0	63
618	LONG-TERM RESULTS OF PHOTODYNAMIC THERAPY FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION WITH PATHOLOGIC MYOPIA. <i>Retina</i> , 2012, 32, 1547-1552.	1.0	30

#	ARTICLE	IF	CITATIONS
619	RETINAL ANGIOMATOUS PROLIFERATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2012, 32, 416-434.	1.0	265
620	INDOCYANINE GREEN ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2012, 32, 288-298.	1.0	131
622	The Cost-effectiveness of Welcome to Medicare Visual Acuity Screening and a Possible Alternative Welcome to Medicare Eye Evaluation Among Persons Without Diagnosed Diabetes Mellitus. <i>JAMA Ophthalmology</i> , 2012, 130, 607-14.	2.6	8
623	Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 992-1000.	2.5	119
624	Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 1001-1010.	2.5	115
625	Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 1388-1398.	2.5	1,550
626	Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. <i>Pharmacogenomics</i> , 2012, 13, 1037-1053.	0.6	27
627	Vascular targeted photodynamic therapy for bleeding gastrointestinal mucosal vascular lesions: A preliminary study. <i>Photodiagnosis and Photodynamic Therapy</i> , 2012, 9, 109-117.	1.3	12
628	Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 2537-2548.	2.5	1,947
629	New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-7.	0.6	15
630	Promising Treatment Strategies for Neovascular AMD: Anti-VEGF Therapy. , 0, , .		0
631	Photodynamic Therapy of Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin: An Analysis of 10 Years of Clinical Results. <i>Journal of Korean Ophthalmological Society</i> , 2012, 53, 59.	0.0	1
632	Photodynamic Therapy for Chronic Central Serous Chorioretinopathy According to Degree of Choroidal Hyperfluorescence. <i>Journal of Korean Ophthalmological Society</i> , 2012, 53, 268.	0.0	1
633	Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis. <i>Recent Patents on Biomedical Engineering</i> , 2012, 5, 83-101.	0.5	22
634	Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy. <i>Graefes' Archive for Clinical and Experimental Ophthalmology</i> , 2012, 250, 803-808.	1.0	13
635	Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. <i>Acta Ophthalmologica</i> , 2013, 91, 42-47.	0.6	50
636	Applied Photochemistry. , 2013, , .		37
637	Corneal heat scar caused by photodynamic therapy performed through an implanted corneal inlay. <i>Journal of Cataract and Refractive Surgery</i> , 2013, 39, 1768-1773.	0.7	7

#	ARTICLE	IF	CITATIONS
638	Single-session photodynamic therapy combined with intravitreal ranibizumab for neovascular age-related macular degeneration: a comprehensive functional retinal assessment. <i>Documenta Ophthalmologica</i> , 2013, 127, 217-225.	1.0	7
639	Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5Åyears of follow-up. <i>Japanese Journal of Ophthalmology</i> , 2013, 57, 301-307.	0.9	10
640	Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration â€“ evaluation in a clinical setting. <i>BMC Ophthalmology</i> , 2013, 13, 84.	0.6	4
641	Liposomal drug delivery systems: From concept to clinical applications. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 36-48.	6.6	3,565
642	Neovascular (Exudative or â€œWetâ€) Age-Related Macular Degeneration. , 2013, , 1183-1212.		4
643	Oral Docosahexaenoic Acid in the Prevention of Exudative Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2013, 120, 1619-1631.	2.5	114
644	Intravitreal Antiâ€“Vascular Endothelial Growth Factor Therapy Versus Photodynamic Therapy for Idiopathic Choroidal Neovascularization. <i>American Journal of Ophthalmology</i> , 2013, 155, 713-719.e1.	1.7	36
645	Age-related eye disease. <i>Maturitas</i> , 2013, 75, 29-33.	1.0	43
646	Five-Year Follow-up Results of Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. <i>American Journal of Ophthalmology</i> , 2013, 155, 438-447.e1.	1.7	50
647	An update on the pharmacotherapy of neovascular age-related macular degeneration. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1017-1028.	0.9	37
648	Photomedicine. , 2013, , 331-347.		2
649	Retinal Laser Therapy. , 2013, , 746-760.		4
650	Pharmacotherapy of Age-Related Macular Degeneration. , 2013, , 1213-1255.		5
651	Combination Therapies for the Treatment of AMD. , 2013, , 247-261.		1
652	Radiation Therapy: Age-Related Macular Degeneration. <i>Developments in Ophthalmology</i> , 2013, 52, 75-84.	0.1	3
654	Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy. <i>Eye</i> , 2013, 27, 353-362.	1.1	24
655	LUCDEX. <i>Retina</i> , 2013, 33, 1600-1604.	1.0	28
656	TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO ANGIOID STREAKS. <i>Retina</i> , 2013, 33, 1300-1314.	1.0	83

#	ARTICLE	IF	CITATIONS
657	OCULAR RISK FACTORS FOR RECURRENCE OF MYOPIC CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2013, 33, 1613-1622.	1.0	26
658	Pharmacogenetics of the Treatment Response of Age-Related Macular Degeneration with Ranibizumab and Bevacizumab. <i>Seminars in Ophthalmology</i> , 2013, 28, 355-360.	0.8	10
659	Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2013, 7, 615.	0.9	12
660	Clinical Manifestation of Retinal Pigment Epithelial Tear after Treatment of Age-Related Macular Degeneration. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1540.	0.0	3
661	Bevacizumab Monotherapy Versus Combined Therapy with Photodynamic Therapy for Occult Choroidal Neovascularization in Age-Related Macular Degeneration. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1554.	0.0	0
662	Comparison of Very Low Fluence and Low Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1046.	0.0	0
663	Comparison of Therapeutic Effect Between Half-Energy Photodynamic Therapy and Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy for 12 Months. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1526.	0.0	3
664	Spectral-domain optical coherence tomography findings in polypoidal choroidal vasculopathy suggest a type 1 neovascular growth pattern. <i>Clinical Ophthalmology</i> , 2014, 8, 1689.	0.9	31
665	Prognostic phenotypic and genotypic factors associated with photodynamic therapy response in patients with age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2014, 8, 2471.	0.9	7
666	Predictive Findings of Visual Outcome in Spectral Domain Optical Coherence Tomography after Ranibizumab Treatment in Age-related Macular Degeneration. <i>Korean Journal of Ophthalmology: KJO</i> , 2014, 28, 386.	0.5	21
667	Comparative study of photodynamic therapy monotherapy versus triplemanagement in age-related macular degeneration. <i>Turkish Journal of Medical Sciences</i> , 2014, 44, 889-895.	0.4	4
668	A new proportion measure of the treatment effect captured by candidate surrogate endpoints. <i>Statistics in Medicine</i> , 2014, 33, 3338-3353.	0.8	8
669	Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. <i>British Journal of Ophthalmology</i> , 2014, 98, 1629-1635.	2.1	67
670	Retinal injury thresholds for 532, 578, and 630nm lasers in connection to photodynamic therapy for choroidal neovascularization. <i>Lasers in Surgery and Medicine</i> , 2014, 46, 54-60.	1.1	3
671	LONG-TERM FUNCTIONAL AND MORPHOLOGIC RETINAL CHANGES AFTER RANIBIZUMAB AND PHOTODYNAMIC THERAPY IN MYOPIC CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2014, 34, 2053-2062.	1.0	19
673	RETINA SPECIALISTS TREATING AGE-RELATED MACULAR DEGENERATION RECOMMEND DIFFERENT APPROACHES FOR PATIENTS THAN THEY WOULD CHOOSE FOR THEMSELVES. <i>Retina</i> , 2014, 34, 1796-1801.	1.0	15
674	Intravitreal ranibizumab for the treatment of fibrovascular pigment epithelial detachment in age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , 2014, 49, 367-376.	0.4	12
675	The Incidence of Neovascular Subtypes in Newly Diagnosed Neovascular Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2014, 158, 769-779.e2.	1.7	167

#	ARTICLE	IF	CITATIONS
676	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). <i>British Journal of Ophthalmology</i> , 2014, 98, 1144-1167.	2.1	463
677	Impact of Vitreomacular Adhesion on Ranibizumab Mono- and Combination Therapy for Neovascular Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2014, 158, 328-336.e1.	1.7	35
678	Porphysome nanotechnology: A paradigm shift in lipid-based supramolecular structures. <i>Nano Today</i> , 2014, 9, 212-222.	6.2	98
679	Neovascular Age-Related Macular Degeneration. <i>Developments in Ophthalmology</i> , 2016, 55, 125-136.	0.1	52
681	Photosensitizers and Photodynamic Therapy: Verteporfin. <i>Developments in Ophthalmology</i> , 2016, 55, 330-336.	0.1	20
682	Long-Term follow-up of Standard Photodynamic Therapy with Standardized Small Spot Size for Diffuse Retinal Pigment Epitheliopathy. <i>European Journal of Ophthalmology</i> , 2015, 25, 229-234.	0.7	1
684	Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19796-19811.	1.8	5
685	A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. <i>Frontiers in Oncology</i> , 2015, 5, 190.	1.3	60
686	Management of neovascular age-related macular degeneration: current state-of-the-art care for&nbsp;optimizing visual outcomes and therapies in&nbsp;development. <i>Clinical Ophthalmology</i> , 2015, 9, 1001.	0.9	35
687	Complement activation and choriocapillaris loss in early AMD: Implications for pathophysiology and therapy. <i>Progress in Retinal and Eye Research</i> , 2015, 45, 1-29.	7.3	189
688	Clinical Characteristics and Current Treatment of Age-Related Macular Degeneration. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a017178-a017178.	2.9	53
689	Synthesis of Hemoglobin Conjugated Polymeric Micelle: A ZnPc Carrier with Oxygen Self-Compensating Ability for Photodynamic Therapy. <i>Biomacromolecules</i> , 2015, 16, 2693-2700.	2.6	121
690	Vascular-targeted photodynamic therapy in the treatment of neovascular age-related macular degeneration: Clinical perspectives. <i>Photodiagnosis and Photodynamic Therapy</i> , 2015, 12, 161-175.	1.3	33
691	Long-Term Results of Photodynamic Therapy for Choroidal Neovascularization in Pediatric Patients with Best Vitelliform Macular Dystrophy. <i>Ophthalmic Genetics</i> , 2015, 36, 168-174.	0.5	15
692	Delivery strategies for treatment of age-related ocular diseases: From a biological understanding to biomaterial solutions. <i>Journal of Controlled Release</i> , 2015, 219, 652-668.	4.8	66
693	Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study. <i>Ophthalmologica</i> , 2015, 233, 66-73.	1.0	19
694	Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland. <i>Eye</i> , 2015, 29, 1156-1161.	1.1	37
695	Vision-Threatening Lesions Developing with Longer-Term Follow-up after Treatment of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015, 122, 153-161.	2.5	26

#	ARTICLE	IF	CITATIONS
696	Structural characterization of novel cationic diC16-amidine bilayers: Evidence for partial interdigitation. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2015, 1848, 127-133.	1.4	7
697	Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation. <i>Clinical Ophthalmology</i> , 2016, 10, 861.	0.9	5
698	Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation. <i>Journal of Ophthalmology</i> , 2016, 2016, 1-12.	0.6	9
699	Understanding the Determinants of Myopic Choroidal Neovascularization and Response to Treatment. <i>European Journal of Ophthalmology</i> , 2016, 26, 511-516.	0.7	6
700	Evolution of Concepts and Technologies in Ophthalmic Laser Therapy. <i>Annual Review of Vision Science</i> , 2016, 2, 295-319.	2.3	9
701	Specific cellular accumulation of photofrin-II in EC cells promotes photodynamic treatment efficacy in esophageal cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2016, 14, 27-33.	1.3	5
702	Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. <i>Progress in Retinal and Eye Research</i> , 2016, 53, 107-139.	7.3	276
703	Antiangiogenic Agents and Photodynamic Therapy. , 2016, , 245-268.		0
704	Five-Year Outcomes with Anti-“Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 1751-1761.	2.5	541
705	Optical Coherence Tomography Angiography of Mixed Neovascularizations in Age-Related Macular Degeneration. <i>Developments in Ophthalmology</i> , 2016, 56, 62-70.	0.1	12
706	Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. <i>The Cochrane Library</i> , 2016, , .	1.5	4
707	Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. <i>Pharmaceutical Research</i> , 2016, 33, 2373-2387.	1.7	1,976
708	Pharmacology of Ocular Therapeutics. , 2016, , .		6
709	The role of Aflibercept in the management of age-related macular degeneration. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 699-709.	1.4	7
710	Photodynamic therapy: current role in the treatment of chorioretinal conditions. <i>Eye</i> , 2016, 30, 202-210.	1.1	85
711	A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. <i>Progress in Retinal and Eye Research</i> , 2016, 50, 1-24.	7.3	284
713	Wet Age-Related Macular Degeneration. <i>ESASO Course Series</i> , 2017, , 1-13.	0.1	0
714	A Multimodal Imaging Guide to the Evaluation and Management of Neovascular Age-Related Macular Degeneration. <i>ESASO Course Series</i> , 2017, , 14-31.	0.1	0

#	ARTICLE	IF	CITATIONS
715	Role of In Vitro Release Methods in Liposomal Formulation Development: Challenges and Regulatory Perspective. <i>AAPS Journal</i> , 2017, 19, 1669-1681.	2.2	57
716	Comparing Ranibizumab Monotherapy and Combination with Single Photodynamic Therapy in Wet AMD: Retreatment and Morphologic Results. <i>European Journal of Ophthalmology</i> , 2017, 27, 470-475.	0.7	5
717	Patchy Chorioretinal Atrophy Changes at the Posterior Pole After Ranibizumab for Myopic Choroidal Neovascularization. , 2017, 58, 6358.		11
718	Application of Various Types of Liposomes in Drug Delivery Systems. <i>Advanced Pharmaceutical Bulletin</i> , 2017, 7, 3-9.	0.6	308
719	Neovascular (Wet) Age-Related Macular Degeneration. , 2017, , 89-116.		3
720	Increased YAP Activation Is Associated With Hepatic Cyst Epithelial Cell Proliferation in ARPKD/CHF. <i>Gene Expression</i> , 2017, 17, 313-326.	0.5	10
721	Long-term Progression of Type 1 Neovascularization in Age-related Macular Degeneration Using Optical Coherence Tomography Angiography. <i>American Journal of Ophthalmology</i> , 2018, 187, 10-20.	1.7	87
722	Baseline data from a multicenter, 5-year, prospective cohort study of Japanese age-related macular degeneration: an AMD2000 report. <i>Japanese Journal of Ophthalmology</i> , 2018, 62, 127-136.	0.9	8
723	Treatment of retinal pigment epithelial detachment secondary to exudative age-related macular degeneration. <i>American Journal of Ophthalmology Case Reports</i> , 2018, 9, 18-22.	0.4	4
724	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. <i>Progress in Retinal and Eye Research</i> , 2018, 65, 127-146.	7.3	205
725	Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. <i>Journal of Pharmaceutical Investigation</i> , 2018, 48, 43-60.	2.7	303
727	Bioengineered and Regenerative Medicine Strategies for Retina Repair. <i>Fundamental Biomedical Technologies</i> , 2018, , 51-86.	0.2	0
728	The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea. <i>PLoS ONE</i> , 2018, 13, e0206690.	1.1	11
729	Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 1877-1885.	0.9	23
730	The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2611.	1.8	22
731	N-acetylcysteine protects against chorioretinal damage induced by photodynamic therapy for experimental choroidal neovascularization in a rat model. <i>Photodiagnosis and Photodynamic Therapy</i> , 2018, 23, 12-17.	1.3	2
732	Intravitreal aflibercept: its role in treatment of neovascular age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2018, 13, 75-86.	0.3	1
733	X-ray radiation-induced and targeted photodynamic therapy with folic acid-conjugated biodegradable nanoconstructs. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 3553-3570.	3.3	44

#	ARTICLE	IF	CITATIONS
735	Developing Therapies for Age-related Macular Degeneration: The Art and Science of Problem-solving. <i>Ophthalmology Retina</i> , 2019, 3, 900-909.	1.2	13
736	Autologous translocation of the choroid and retina pigment epithelial cells(RPE) in age-related macular degeneration: Monitoring the viability of choroid and RPE patch with indocyanine green angiography(ICGA) and fundus autofluorescence(FAF). <i>Photodiagnosis and Photodynamic Therapy</i> , 2019, 28, 318-323.	1.3	7
737	Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1755-1764.	1.9	17
738	<i>Polymeric Nanomaterials.</i> , 2019, , 1-66.		25
739	Polymeric Nanoparticulates as Efficient Anticancer Drugs Delivery Systems. <i>Advanced Structured Materials</i> , 2019, , 55-84.	0.3	3
741	The State of the Art of Investigational and Approved Nanomedicine Products for Nucleic Acid Delivery. , 2019, , 421-456.		7
742	&lt;p&gt;Treatment of large avascular retinal pigment epithelium detachments in age-related macular degeneration with aflibercept, photodynamic therapy, and triamcinolone acetonide&lt;/p&gt;. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 233-241.	0.9	5
743	Nanoscale delivery systems in treatment of posterior ocular neovascularization: strategies and potential applications. <i>Therapeutic Delivery</i> , 2019, 10, 737-747.	1.2	9
744	Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2019, 126, 55-63.	2.5	113
745	In Vivo and in Vitro Demonstration of Gold Nanorod Aided Photothermal Presoftening of B16F10 Melanoma for Efficient Chemotherapy Using Doxorubicin Loaded Graphene Oxide. <i>ACS Applied Bio Materials</i> , 2019, 2, 533-543.	2.3	13
746	Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. <i>Journal of the American Heart Association</i> , 2019, 8, e011343.	1.6	50
747	Looking Back: Fluorescein Angiography and Optical Coherence Tomography and the First Century of the American Journal of Ophthalmology. <i>American Journal of Ophthalmology</i> , 2019, 202, 133-150.	1.7	3
748	<i>Trends in Nanotechnology for Practical Applications.</i> , 2019, , 297-325.		11
749	Fundamentals, challenges, and nanomedicineâ€based solutions for ocular diseases. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2019, 11, e1548.	3.3	43
750	Analysis of the Clinical Profile and Management of Inflammatory Choroidal Neovascular Membranes in Uveitic Eyes: A Study from a Tertiary Referral Center. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 424-434.	1.0	8
751	PHOTODYNAMIC THERAPYâ€INDUCED ACUTE EXUDATIVE MACULOPATHY. <i>Retina</i> , 2020, 40, 135-144.	1.0	13
752	Age-Related Macular Degeneration Preferred Practice PatternÂ®. <i>Ophthalmology</i> , 2020, 127, P1-P65.	2.5	167
753	The Yin and Yang of PDT and PTT. <i>Photochemistry and Photobiology</i> , 2020, 96, 219-231.	1.3	33

#	ARTICLE	IF	CITATIONS
754	Subretinal pigment epithelium fibrotic tissue morphological changes after a single anti-vascular endothelial growth factor injection in age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2020, 104, 1085-1088.	2.1	4
755	Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020, 127, 784-792.	2.5	16
756	TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VEGF VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. <i>Retina</i> , 2020, 40, 1665-1672.	1.0	17
757	Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration. , 2020, , .		1
758	Long-Term Follow-up of Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Anti-VEGF Vascular Endothelial Growth Factor Injections. <i>Ophthalmology Retina</i> , 2020, 4, 1047-1053.	1.2	10
759	Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease. <i>Topics in Medicinal Chemistry</i> , 2020, , 125-160.	0.4	3
760	Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. <i>JAMA Ophthalmology</i> , 2020, 138, 935.	1.4	93
761	CRISPR Technology for Ocular Angiogenesis. <i>Frontiers in Genome Editing</i> , 2020, 2, 594984.	2.7	8
762	Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. <i>The Cochrane Library</i> , 2020, 2020, CD012208.	1.5	52
763	Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy. <i>Scientific Reports</i> , 2020, 10, 8337.	1.6	11
764	Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. <i>Clinical and Experimental Ophthalmology</i> , 2020, 48, 946-955.	1.3	1
765	Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2020, 127, S135-S145.	2.5	36
766	A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration. <i>BMC Ophthalmology</i> , 2020, 20, 21.	0.6	1
767	Investigation on the chiral recognition mechanism between verteporfin and cholate salts by capillary electrophoresis. <i>Journal of Separation Science</i> , 2020, 43, 2905-2913.	1.3	7
768	Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 364-376.	6.6	46
769	Microviscosity and temperature sensors: The twists and turns of the photophysics of conjugated porphyrin dimers – a SPP/JPP Young Investigator Award paper. <i>Journal of Porphyrins and Phthalocyanines</i> , 2020, 24, 1372-1386.	0.4	2
770	Graphene oxide as broadband hyperthermic agent and chemo-photothermal dissolution of kidney-stone mimicking calcium oxalate crystals. <i>Journal of Photochemistry and Photobiology A: Chemistry</i> , 2021, 405, 112917.	2.0	4
771	Pharmacotherapy of Age-Related Macular Degeneration. , 2021, , 1-26.		0

#	ARTICLE	IF	CITATIONS
772	Choroidal Neovascularization. , 2021, , 271-293.		0
773	Combination therapy of dry cupping and Pece Kau'a (traditional therapy in Bima, West Nusa Tenggara) Tj ETQq1 1 0.784314 rgBT /Over Scientific Research, 2021, 7, 56-62.	0.2	0
774	Transient accumulation of subretinal fluid after half-fluence photodynamic therapy in neovascular age-related macular degeneration. BMC Ophthalmology, 2021, 21, 98.	0.6	1
775	The Past and Present of Photodynamic Therapy in Ophthalmology. Nippon Laser Igakkaishi, 2021, 42, 78-88.	0.0	0
776	The 100 most-cited papers on age-related macular degeneration: a bibliographic perspective. BMJ Open Ophthalmology, 2021, 6, e000823.	0.8	4
777	YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. Developmental Biology, 2021, 475, 205-221.	0.9	62
778	Current Indications for Photodynamic Therapy in Retina and Ocular Oncology. Current Ophthalmology Reports, 2021, 9, 107-116.	0.5	2
779	Dose-Related Structural Effects of Photodynamic Therapy on Rabbit Choroidal Structure. Ophthalmic Research, 2021, 64, 1037-1047.	1.0	2
780	Investigating the Application of Liposomes as Drug Delivery Systems for the Diagnosis and Treatment of Cancer. International Journal of Biomaterials, 2021, 2021, 1-16.	1.1	34
781	Intravitreal treatment of severe ocular von Hippel-Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial. Clinical and Experimental Ophthalmology, 2021, 49, 1048-1059.	1.3	5
782	Current Management of Age-Related Macular Degeneration. Advances in Experimental Medicine and Biology, 2021, 1256, 295-314.	0.8	6
783	Druggable Targets and Therapeutic Agents for Disorders of the Back of the Eye. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , 495-563.	0.2	1
784	Review of Emerging Treatments for Age-Related Macular Degeneration. , 2012, , 1-46.		2
785	Nutritional Supplementation in Age-related Macular Degeneration. , 2007, , 105-111.		2
786	Quantitative Fluorescein Angiography. , 2006, , 917-947.		1
787	Neovascular (Exudative) Age-Related Macular Degeneration. , 2006, , 1075-1113.		11
788	Choroidal Neovascular Membrane in Degenerative Myopia. , 2006, , 1115-1133.		10
789	Retinal Pigment Epithelium and Photoreceptor Transplantation Frontiers. , 2006, , 2597-2613.		8

#	ARTICLE	IF	CITATIONS
790	Dual Stimuli-Responsive Vesicular Nanospheres Fabricated by Lipopolymer Hybrids for Tumor-Targeted Photodynamic Therapy. <i>Biomacromolecules</i> , 2016, 17, 20-31.	2.6	34
791	Transpupillary thermotherapy of occult CNV with no or minimally classic CNV in age-related macular degeneration. <i>Seminars in Ophthalmology</i> , 2001, 16, 90-96.	0.8	20
792	TREATMENT OF ANGIOMATOUS LESIONS OF THE RETINA WITH PHOTODYNAMIC THERAPY. <i>Retina</i> , 2002, 22, 228-232.	1.0	46
793	INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH OR WITHOUT PRIOR TREATMENT WITH PHOTODYNAMIC THERAPY. <i>Retina</i> , 2010, 30, 85-92.	1.0	15
794	Long-term results of rescue photodynamic therapy for type 1 neovascularization refractory to anti-vascular endothelial growth factor. <i>Acta Ophthalmologica</i> , 2021, 99, e899-e907.	0.6	6
795	Guidance for the treatment of neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2007, 85, 486-494.	0.4	72
796	Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes. <i>British Journal of Ophthalmology</i> , 2007, 91, 166-173.	2.1	33
797	Migration and proliferation of retinal pigment epithelium on extracellular matrix ligands. <i>Journal of Rehabilitation Research and Development</i> , 2006, 43, 713.	1.6	14
798	Comparison of the efficacy of anti-VEGF monotherapy versus PDT and intravitreal anti-VEGF combination treatment in AMD: a Meta-analysis and systematic review. <i>International Journal of Ophthalmology</i> , 2016, 9, 1028-37.	0.5	12
799	Efficacy of combined photodynamic therapy and sub-Tenon's capsule injection of triamcinolone acetonide for age-related macular degeneration. <i>Journal of Medical Investigation</i> , 2009, 56, 116-119.	0.2	8
800	Age-related Macular Degeneration: Current Knowledge of Zinc Metalloproteinases Involvement. <i>Current Drug Targets</i> , 2019, 20, 903-918.	1.0	3
801	The Treatment of Wet Age-Related Macular Degeneration. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2009, 106, 312-7.	0.6	19
802	The Effect of Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. <i>Journal of Korean Ophthalmological Society</i> , 2007, 48, 1048.	0.0	6
803	Oral Fluorescein Angiography in Patients With Choroidal Neovascularization and Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2003, 34, 17-24.	0.4	6
804	Ocular Photodynamic Therapy in Choroidal Neovascularization Complicating Idiopathic Central Serous Chorioretinopathy. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2004, 35, 168-171.	0.4	11
805	Indocyanine Green Dye-Enhanced Transpupillary Thermotherapy of Classic Subfoveal Choroidal Neovascularization. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2004, 35, 197-206.	0.4	3
806	Results 28 Months Following Transpupillary Thermotherapy for Classic and Occult Choroidal Neovascularization in Patients With Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2005, 36, 94-99.	0.4	6
807	Photodynamic Therapy in Young Patients. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2006, 37, 182-189.	0.4	10

#	ARTICLE	IF	CITATIONS
808	Transpupillary Thermotherapy With Indocyanine Green Dye Enhancement for the Treatment of Occult Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2006, 37, 272-277.	0.4	5
809	Photodynamic Therapy for Choroidal Neovascularization Associated With Submacular Hemorrhage in Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2006, 37, 278-283.	0.4	17
810	ICG Angiography-Guided Photodynamic Therapy for Large Pigment Epithelial Detachments in Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2006, 37, 358-363.	0.4	13
811	Combined Photodynamic Therapy and Intravitreal Triamcinolone Acetonide Injection for Neovascular Age-Related Macular Degeneration With Pigment Epithelium Detachment. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2006, 37, 455-461.	0.4	14
812	Large Submacular Hemorrhage Following PDT With Verteporfin in Patients With Occult CNVM Secondary to Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2007, 38, 64-68.	0.4	5
813	Treatment of Vasoproliferative Tumors with Photodynamic Therapy. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2008, 39, 143-145.	0.4	23
814	Photodynamic Therapy for Age-Related Macular Degeneration Treatment: Epidemiological and Clinical Analysis of a Long-Term Study. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2009, 40, 277-284.	0.4	12
815	Photodynamic Therapy With and Without Adjunctive Intravitreal Triamcinolone Acetonide: A Retrospective Comparative Study. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2009, 40, 561-569.	0.4	8
816	Polypoidal Choroidal Vasculopathy in Taiwanese Patients. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2009, 40, 576-581.	0.4	50
817	Acute Severe Visual Decrease After Photodynamic Therapy with Verteporfin: Spectral-Domain OCT Features. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, S85-8.	0.4	10
818	Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Ophthalmology</i> , 2014, 7, 541-9.	0.5	12
819	Meta-analysis of best corrected visual acuity after treatment for myopic choroidal neovascularisation. <i>International Journal of Ophthalmology</i> , 2014, 7, 720-5.	0.5	3
820	Role of ranibizumab in management of macular degeneration. <i>Indian Journal of Ophthalmology</i> , 2007, 55, 421.	0.5	13
821	Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration. <i>Indian Journal of Ophthalmology</i> , 2007, 55, 431.	0.5	23
822	Management of neovascular Age-related macular degeneration: A review on landmark randomized controlled trials. <i>Middle East African Journal of Ophthalmology</i> , 2016, 23, 27.	0.5	24
823	Photodynamic therapy and intravitreal bevacizumab with versus without triamcinolone for neovascular age-related macular degeneration; a randomized clinical trial. <i>Journal of Ophthalmic and Vision Research</i> , 2014, 9, 469.	0.7	3
824	Therapeutic Modalities of Exudative Age-related Macular Degeneration. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2014, 68, 204.	0.4	10
825	Cell Membrane-Coated Mimics: A Methodological Approach for Fabrication, Characterization for Therapeutic Applications, and Challenges for Clinical Translation. <i>ACS Nano</i> , 2021, 15, 17080-17123.	7.3	73

#	ARTICLE	IF	CITATIONS
826	Clinical Applications of Photodynamic Therapy. , 2003, , .		0
828	Current status of macular translocation surgery. , 2004, , 101-114.		0
829	Two-year results after macular translocation with 360° retinotomy. , 2004, , 115-121.		0
830	Retinal Laser Therapy: Biophysical Basis and Applications. , 2006, , 539-553.		2
831	åŠé½çé»,æ-‘å%æ€šç-‡ã«ã³/4ãªã,ã...%øç-šãŠ›ã½çš,,ç™,æ³•ã®ã½œç™”. Nippon Laser Igakkaishi, 2006, 27, 32-35.0		1
832	Surgical Removal of Subretinal Choroidal Neovascular Membranes. , 2006, , 2545-2554.		0
833	Pharmacotherapy of Age-Related Macular Degeneration. , 2006, , 1211-1239.		1
834	Limited Macular Translocation. , 2006, , 2561-2580.		0
835	Altersbedingte Makuladegeneration. Pharma-Kritik (discontinued), 2006, 27, .	0.0	0
836	Photodynamic Therapy for Age-Related Macular Degeneration. The Review of Laser Engineering, 2007, 35, 503-508.	0.0	0
837	VALUE-BASED MEDICINE ANALYSIS: OPHTHALMIC COST-UTILITY ANALYSES. Evidence-Based Ophthalmology, 2007, 8, 181-187.	0.0	1
838	The Temporal Sequence of Combined Intravitreal Triamcinolone Acetonide and Photodynamic Therapy for Exudative Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2008, 39, 12-16.	0.4	0
839	Degenerative Retinopathies. , 2008, , 443-472.		0
841	Subretinal Hemorrhage After Photodynamic Therapy for Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2008, 49, 1603.	0.0	0
844	Photodynamic Therapy With Verteporfin using Half Fluence for Chronic Central Serous Chorioretinopathy. Journal of Korean Ophthalmological Society, 2009, 50, 1326.	0.0	5
847	Geriatric Ophthalmology. , 2011, , 513-523.		0
848	Combination Therapy with Ocular Photodynamic Therapy for Age-Related Macular Degeneration. , 2011, , 99-118.		0
849	Kombinationstherapien zur Behandlung der AMD. , 2011, , 253-268.		0

#	ARTICLE	IF	CITATIONS
850	Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment. Journal of Clinical & Experimental Ophthalmology, 2012, 02, .	0.1	0
851	Die Bedeutung der PDT für vaskuläre Erkrankungen der Netzhaut. , 2012, , 47-65.		0
852	Combination Treatment Strategies in Neovascular AMD. , 2012, , 501-515.		0
853	Modalidades de Tratamiento de la Degeneración Macular Asociada a la Edad. Highlights of Ophthalmology, 2013, 41, 2-4.	0.0	0
854	Reliable Therapeutic Modalities To Treat Age-Related Macular Degeneration. Highlights of Ophthalmology, 2013, 41, 2-4.	0.0	0
855	Choroidal Neovascularization. , 2014, , 211-230.		0
858	Nanotechnology for Omics-Based Ocular Drug Delivery. Advances in Chemical and Materials Engineering Book Series, 2015, , 152-166.	0.2	0
859	Ocular and Orbital: Viewpoint Surgery. , 2015, , 765-772.		0
860	Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study. Digital Journal of Ophthalmology: DJO, 2016, 22, 46-53.	0.2	6
861	Photodynamic Therapy for Pseudophakic Eyes Compared to Eyes With Cataract. Ophthalmic Surgery Lasers and Imaging Retina, 2016, 47, 1132-1136.	0.4	1
863	Nanotechnology for Omics-Based Ocular Drug Delivery. , 2017, , 366-381.		0
864	Refractory Neovascular Age-related Macular Degeneration. Journal of Retina, 2017, 2, 51-59.	0.1	0
865	Nanotechnology for Omics-Based Ocular Drug Delivery. , 2018, , 283-298.		0
866	Verteporfin Photodynamic Therapy for the Treatment of Choroidal Conditions An Overview. US Ophthalmic Review, 2019, 12, 69.	0.2	0
867	Oftalmolojide fotodinamik tedavi. Ege Tıp Dergisi, 0, , 289-294.	0.1	0
868	REDUCED VASCULAR DENSITY IN THE CHOROID AFTER TREATMENT WITH PHOTODYNAMIC THERAPY COMBINED WITH AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2021, 41, 156-161.	1.0	3
869	Clinical Trials Related to Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. , 2020, , 259-281.		1
870	Novel Therapeutic Strategies For Posterior Segment Neovascularization. , 2008, , 445-526.		0

#	ARTICLE	IF	CITATIONS
873	The Role of Photodynamic Therapy in Retinal Vascular Disease. , 2007, , 239-255.		1
874	Therapie der idiopathischen CNV mittels photodynamischer Therapie. , 2008, , 7-18.		0
875	Photodynamische Therapie bei solitärem choroidalen Hämangiom. , 2008, , 29-45.		0
878	Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis). Transactions of the American Ophthalmological Society, 2008, 106, 357-82.	1.4	7
879	Angioid streaks, clinical course, complications, and current therapeutic management. Therapeutics and Clinical Risk Management, 2009, 5, 81-9.	0.9	80
880	Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration. Clinical Ophthalmology, 2008, 2, 159-66.	0.9	1
881	Intravitreal bevacizumab: an analysis of the evidence. Clinical Ophthalmology, 2007, 1, 273-84.	0.9	8
882	Age related macular degeneration. Clinical Evidence, 2007, 2007, .	0.2	4
883	Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration. Core Evidence, 2008, 2, 273-94.	4.7	8
884	Low-fluence photodynamic therapy combinations in the treatment of exudative age-related macular degeneration. International Journal of Ophthalmology, 2012, 5, 377-83.	0.5	1
885	Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration. Journal of Ophthalmic and Vision Research, 2008, 3, 95-101.	0.7	6
886	Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society, 2014, 112, 160-98.	1.4	20
888	Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, , 1.	1.0	4
889	Long-term characteristics of exudative age-related macular degeneration in Japanese patients. PLoS ONE, 2021, 16, e0261320.	1.1	4
891	Pharmacotherapy of Age-Related Macular Degeneration. , 2022, , 3619-3644.		1
893	Aspects of Antiviral Strategies Based on Different Phototherapy Approaches: Hit by the Light. Pharmaceuticals, 2022, 15, 858.	1.7	5
894	Recent Advancements in Nanomaterials for Photodynamic Therapy of Cancers. , 2022, , 1261-1284.		0
895	Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brucicuzumab. Journal of Clinical Medicine, 2022, 11, 5517.	1.0	7

#	ARTICLE	IF	CITATIONS
896	Photodynamic Therapy-Induced Acute Exudative Maculopathy (PAEM): Prevalence, Impact and Management Strategies. <i>Clinical Ophthalmology</i> , 0, Volume 16, 3145-3154.	0.9	4
897	Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations. <i>Pharmaceutics</i> , 2022, 14, 1842.	2.0	15
898	Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration. <i>Biomolecules</i> , 2022, 12, 1629.	1.8	20
902	Comparison of Real-world Treatment Outcomes between Type 1 and Type 2 Choroidal Neovascularization. <i>Journal of Retina</i> , 2022, 7, 98-107.	0.1	0
904	Optical coherence tomography angiography patterns of type 1 macular neovascularization in age-related macular degeneration patients. <i>European Journal of Ophthalmology</i> , 2023, 33, 1697-1705.	0.7	1
905	The Natural History of Occult Choroidal Neovascularisation Associated With Age-related Macular Degeneration. A Systematic Review. <i>Annals of the Academy of Medicine, Singapore</i> , 2006, 35, 145-150.	0.2	12
906	Retrospective Review of Eyes with Neovascular Age-related Macular Degeneration Treated with Photodynamic Therapy with Verteporfin and Intravitreal Triamcinolone. <i>Annals of the Academy of Medicine, Singapore</i> , 2006, 35, 701-705.	0.2	9
908	Photodynamic Therapy for Choroidal Neovascularisation Secondary to Inflammatory Chorioretinal Disease. <i>Annals of the Academy of Medicine, Singapore</i> , 2006, 35, 198-202.	0.2	30
909	Common retinal disorders. , 2018, , 413-435.		0
910	Transport of drugs using liposomes. , 2023, , 127-140.		0
912	New Avenues of Delivery (Subretinal Gene Therapy, Port Delivery, Suprachoroidal). <i>Current Practices in Ophthalmology</i> , 2023, , 339-351.	0.1	0